(51) International Patent Classification [4] : C12Q 1/68, 1/70 C07C 107/00, G01N 33/566	**A1**	(11) International Publication Number: WO 89/09833
		(43) International Publication Date: 19 October 1989 (19.10.89)

(54) Title: LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS

(57) Abstract

A broad class of pharmaceutical agents which react directly with electron carriers or with reactive species produced by electron transport to release a pharmacologically active molecule to effect a therapeutic functional change in the organism by a receptor or nonreceptor mediated action.

- 1 -

LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS

FIELD OF THE INVENTION

The present invention relates to therapeutic pharmaceutical agents which are activated intracellularly by reaction with cellular electron carriers or free radicals to cause release of a free and active drug molecule.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation in part of my co-pending U.S. Patent Application Serial No. 948,326, entitled LUMINIDE CLASS OF PHARMACEUTICALS, filed December 31, 1986.

BACKGROUND OF THE INVENTION

The effects of the preponderance of drugs result from their interaction with functional macromolecular components of the organism. Such interaction alters the function of the pertinent cellular component and thereby initiates the series of biochemical and physiological changes that are characteristic of the response to the drug. The term receptor denotes the component of the organism with which the chemical agent interacts. There are fundamental corollaries to the statement that the receptor for a drug can be any functional macromolecular component of the organism. One is that a drug is potentially capable of altering the rate at which any bodily function proceeds; a second is that, by virtue of interactions with specific receptors, drugs do not create effects

- 2 -

but merely modulate the rates of ongoing functions.
A simple pharmacological dictum thus states that a
drug cannot impart a new function to a cell.
Functional changes due to a drug result from either
enhancement or inhibition of the unperturbed rate.
Furthermore, a drug that has no direct action can
cause a functional change by competition for a
binding site with another, active regulatory ligand
of the receptor. Drugs are termed agonists when they
cause effects as a result of direct alteration of the
fundamental properties of the receptor with which
they interact. Compounds that are themselves devoid
of intrinsic pharmacological activity but cause
effects by inhibition of the action of a specific
agonist (eg. by competition for agonist binding
sites) are designated as antagonists.

At least from a numerical standpoint, the
proteins of the cell form the most important class of
drug receptors. Obvious examples are the enzymes of
crucial metabolic or regulatory pathways (eg.,
tyrosine hydroxylase; 3-hydroxy-3-methylglutaryl -
CoA reductase), but of equal interest are proteins
involved in transport processes (eg. Ca^{2+} - ATPase;
Na^+ - K^+ - ATPase) or those that are protein
kinases which activate other proteins as a
consequence of their binding a secondary messenger
such as cAMP. Specific binding properties of other
cellular constituents can be exploited. Thus,
nucleic acids are important drug receptors,
particularly for chemotherapeutic approaches to the
control of malignancy, and plant lectins shown
remarkable specificity for recognition of specific
carbohydrate residues in polysaccharides and
glycoproteins. Small ions such as Ca^{2+} which can
function as a regulatory ion or Fe^{2+} which can

serve as an essential enazmatic cofactor can be
exploited as drug receptors. And, drugs can also
produce a functional change by a nonreceptor-mediated
action. Certain drugs that are structural analogues
of normal biological constituents may be incorporated
into cellular components and thereby alter their
function. This has been termed a "counterfeit
incorporation mechanism" and has been implemented
with analogues of purines and pyrimidines that can be
incorporated into nucleir acids and that have utility
in cancer chemotherapy and that have antiviral
activity. Also, specific constituents of pathogens
can be exploited as receptors. For example, the
electron carriers of bacterial can serve as receptors
as described in my previous U.S. Patent Application
Serial No. 948,326, and the replicative enzymes of
viruses can be serve as receptors as described below
for the virus HIV. Many compounds are known which
have receptor or nonreceptor mediated in vitro
activity as appears in Handbook of Enzyme Inhibitors,
Mahendra Kumor Jain, 1982, Wiley Interscience, New
York, hereby incorporated by reference. However,
only a small percentage produce the desired
functional change in vivo or have a high therapeutic
ratio because they are toxic in their free form; they
are rapidly inactivated or excreted; or, they cannot
obtain access to their target receptor or site of
action because they are impermeant to cells or
biological barriers such as the blood brain barrier
due to unfavorable energetics due, for example, to
the possession of polar or charge groups; or, they
are toxic as a consequence of being nonselective with
regards to their access to and action with receptors
in one biological environment or compartment relative
to another. In these cases, compounds which

- 4 -

demonstrate in vitro efficacy are ineffective
therapeutics.

SUMMARY OF THE INVENTION

A broad class of pharmaceutical agents is
disclosed herein as the Luminide class of
pharmaceuicals. Luminide agents are three part or
four part molecules where each part is a
functionality with a defined purpose. Exemplary
Luminides are A-B-C , D-A-B-C, A-D-B-C, and A-B-C
$$\begin{matrix} & & \backslash \\ & & D \end{matrix}$$

where A represents a functionality which is
activatable by the environment and capable of
transferring energy from its own excited state to the
B functionality which is an energy acceptor. Upon
receiving energy from A, B achieves an excited state
which relaxes through the heterolytic cleavage of the
covalent bond of B with C where C is a drug moiety
which is released into the intracellular compartment
where activation of A occured. Released C can act
locally or at a distant site. D serves as an
electron transfer functionality which gains (loses)
electrons from (to) the environment and donates
(accepts) electrons to (from) A to activate it so
that the energy of excited A is transferred to B with
release of C as occurs for the three functionality
case.

In both cases, free C is a drug molecule. The
released drug molecule effects a therapeutic
functional change by a mechanism which comprises
receptor mediated mechanisms including reversible or
irreversible competitve agonism or antagonism
including a suicide substrate or transition state
analogue mechanism or a noncompetitive or

uncompetitve agonism or antagonism or the action is by a nonreceptor mediated mechanism including a "counterfeit incorporation mechanism".

The chemical and physical properties of the Luminide agents such as permeance and reactivity to different oxidoreductase enzymes, electron carriers, or different free radicals including those of oxygen are exploited to control the environment into which C is released. Permeance of the Luminide agent to the blood brain barrier or cell membranes, or affinity of the Luminide agent to plasma proteins which results in a decreased excretion rate relative to free C, or lack of reactivity of extracellular enzymes with the Luminide agent relative to free C are exemplary mechanism where by Luminides provide for the release of active free C in the proper biological compartment or in the presence of the target receptor so that the desired therapeutic change is achieved. Thus, Luminides serve as therapeutic drugs. And, the present invention, Luminides, a broad class of pharmaceutical agents comprises antilipidemic drugs, anticholesterol drugs, contraceptive agents, anticoagulants, anti-inflamatory agents, immuno-suppressive drugs, antiarrhythmic agents, antineoplastic drugs, antihypertensive drugs, epinephrine blocking agents, cardiac inotropic drugs, antidepressant drugs, diuretics, antifungal agents, antibacterial drugs, anxiolytic agents, sedatives, muscle relaxants, anticonvulsants, agents for the treatment of ulcer disease, agents for the treatment of asthma and hypersensitivity reactions, antithroboembolic agents, agents for the treatment of muscular dystrophy, agents to effect a therapeutic abortion, agents for the treatment of anemia, agents to improve allograft survival, agents for the

treatment of disorders of purine metabolism, agents
for the treatment of ischemic heart disease, agents
for the treatment of opiate withdrawal, agents which
activate the effects of secondary messenger inositol
triphosphate, agents to block spinal reflexes, and
antiviral agents including a drug for the treatment
of AIDS.

DETAILED DESCRIPTION OF THE INVENTION

Electron transferring and transporting elements
are ubiquitous and are necessary for life. All
eukaryotic and prokaryotic organisms depend on
electron transferring and transporting elements which
include metal containing hemes and nonmetal
containing molecules such as flavins to convert the
energy stored in the chemical bonds of foodstuffs
into a form utilizable for the maintenance of the
highly negative entropic state of life. The chemical
energy conversion process generally involves a
coupled series of electron carriers which is called
an electron transport chain.

Free radicals of oxygen are produced during
aerobic respiration in mitochondria as electrons are
carried by electron carriers of the electron
transport chain to the ultimate electron acceptor,
oxygen, and superoxide and peroxide, partial
reduction products of oxygen, are continuously
produced during cytosolic hydroxylation and
oxygenation reactions as well as during other
reactions which involve enzymatic reduction of
oxygen. The cytosol as well as mitochondria of
aerobic cells contain high concentrations of the
enzyme superoxide dismutase which converts superoxide
into hydrogen peroxide and molecular oxygen. Oxygen

- 7 -

radicals which include hydrogen peroxide and
superoxide are found in greater concentration in the
mitochondria relative to the cytosol because
reduction of oxygen occurs to a greater extent in the
former compartment; however, appreciable
concentration are found in both compartments.

Luminides are agents which are permeant to the
desired biological compartment which undergo an
oxidation reduction reaction with the target cell's
electron carriers or react with free radicals
produced as a consequence of electron transport and
release a drug moiety into the desired compartment in
active form to effect a greater therapeutic effect or
therapeutic ratio relative to the free C agent as a
consequence of altered pharmacokinetics or
pharmacodynamics such as a desirable kinetics of
release, a resistance to inactivation or excretion,
greater solubility, enhanced absorption, a diminished
toxicity, or greater access to the cellular or
biological compartment which is the site of action of
C.

Luminide agents are three or four part molecules
where each part is a functionality with a defined
purpose. Exemplary Luminides are A-B-C, D-A-B-C,
A-D-B-C and A-B-C
                 |
                 D

where A represents a functionality which undergoes an
oxidation reduction reaction where electrons are
transferred directly between A and the target cell's
electron carriers or the electrons are transferred
indirectly through an electron transfer
functionality, D, which is described in more detail
below. Alternatively, A represents a functionality
which undergoes a reaction with free radicals of
oxygen which are produced as a consequence of

electron transport. An excited state is produced in
A as a consequence of its participation in one of
these reactions. Then A undergoes intramolecular
energy transfer from its own excited state to the B
functionality which is an energy acceptor. Upon
receiving energy from A, B achieves an excited state
which relaxes through heterolytic cleavage of the
covalent bond of B with C where C is a drug moiety
which is released into the environment. D serves as
an electron transfer functionality which gains
(loses) electrons from (to) the environment and
donates (accepts) electrons to (from) A to activate
it so that the energy of excited A is transferred to
B with release of C as occurs for the three
functionality case. In both cases, free C is a drug
molecule. The released drug molecule effects a
therapeutic functional change by a mechanism which
comprises receptor mediated mechanisms including
reversible and irrereversible competitive agonism or
antagonism including a molecle known as a suicide
substrate or a transition state analogue mechanism or
a noncompetitive or uncompetitive agonism or
antagonism or the action is by a nonreceptor mediated
mechanism including a "counterfeit incorporation
mechanism".

The energy donating funtionality, A, is a
molecule which reacts as previously described to form
an excited state of high enough energy so that this
subsequently transferred energy is of sufficient
magnitude to break the covalent bond between the drug
functionality, C, and the energy acceptor
functionality, B. Chemiluminescent molecules can
form highly excited states of the proper magnitude of
energy, can undergo oxidation reduction reactions or
react with free radicals, and possess a metastable

excited state from which intramolecular energy transfer can occur; thus, they can serve as the A functionality. In general, chemiluminescent molecules relevant to this invention can be placed into three categories: 1) molecules undergoing reaction involving peroxides and oxygen free radicals; 2) molecules undergoing reaction involving oxidation or reduction and 3) molecules undergoing both reaction with peroxides and oxygen free radicals followed by an oxidation or reduction reaction. Molecules of the first category include Lophine and its derivatives, acridinium esters and acridans, tetraphenylpyrrole, phthalhydrazides, acyloins, biacridinium salts, vinylcarbonyls, vinylnitriles, tetrakis (dimethylamino) ethylene, acylperoxides, indoles, tetracarbazoles and active oxalates. Molecules belonging to the second category include ruthenium chelates 2, 6-diaminopyrene, or cation radicals and molecules which follow a Chemically Initiated Electron Exchange Luminescence mechanism such as certain dioxetans and dioxetanones. Dioxene derivatives belong to the third category. They form a dioxetan by reation with superoxide and then produce efficient chemiluminescence by a CIEEL mechanism.

As an example from the first category, the chemiluminescent compound, luminol, has a chemiluminescent maximum in the region 390-400 nm in an aqueous solution. Chemiluminescence is produced by the reaction of luminol with oxygen free radicals where a large fraction of the product molecules are formed in their excited state. The nature of the excited state is electronic, and it has a mean lifetime of the order of 10^{-8} seconds which is typically ten thousand times the period of a

molecular vibration. Emission involves a quantum
mechanically allowed singlet to singlet transition
with energy of the order of 75 Kcal/mole. The
quantum yield for forming the excited electronic
state is 0.5. Because luminol undergoes a
chemiluminescent reaction with oxygen radicals, this
compound has been used as a molecular probe for these
radicals by linkage to a molecule which directs the
probe to a cellular compartment. For example, when
luminol is attached to carnitine, the probe is
transported into mitochondria and the intensity of
chemiluminescence produced is proportional to the
magnitude of electron transport activity which
produces oxygen radicals. The chemiluminescent
molecule, lucigenin, is also used as a probe for
oxygen free radicals.

As for members of the second category,
chemiluminescent molecules which undergo a redox
reaction to produce an excited state react directly
with electron carriers of the cell or undergo a redox
reaction with the electron transfer functionality D.

As for the third category, a D functionality is
optional. A chemiluminescent molecule of this
category reacts with oxygen free radicals and forms
an excited state, and chemiluminescence is produced
but properties such as quantum yield or the relative
ratio of singlet to triplet excited state can be
altered by the transfer of electrons involving for
example a D functionality. See Table 1 below for
chemiluminescent molecules.

- 11 -

Table 1 Representative Chemiluminescent Molecules

<u>Name</u>   <u>Structure</u>

2, 6-diaminopyrene

Aminophthalhydrazide

Dioxene

Imidazole derivaties

Sulfonyloxamides

Indole derivatives

Tetrakis(dialkylamino)ethylene

2,5,7,8-tetraoxabicyclo-[4.2.0.]
octane

Dioxetan

Lucigenin

Lophine

Acridinium esters

Active oxalate

Tris-2,2'-bipyridinedichlororuthenium (II)

Dioxetanone

Dipheyl peroxide

- 15 -

Exemplary energy acceptor molecules include those which demonstrate photochromic behavior with electromagnetic radiation and bleaching agents. If the A functionality is chemiluminescent, then the B functionality is such that the photodissociative drug release spectrum of B overlaps the chemiluminescence spectrum of A.

Triarylmethane dyes react with cyanide to form nitriles called leucocyanides which liberate cyanide ion with a quantum yield of approximately one when irradiated with UV light in the wavelength range of 250 to 320 nm.

The spectrum of the photorelease reaction of cyanide ion can be extended to longer wavelengths in the case of triarylmethane dyes by substitutions of a naphthylene for an aryl group and also by using cationic polymethine dyes. The latter form nitriles, which are thermally stable, by the reaction of the carbonium ion of the dye with cyanide. The formation of the nitrile causes the colored dye to be bleached as is the case with triarylmethane dyes, and cyanide is released as the dye becomes colored upon absorption of 320-415 nm. Reversible bleaching by an agent and coloration by light is photochromic behavior.

Cationic dyes demonstrate this behavior and include di and triarylmethane dyes, triarylmethane lactones and cyclic ether dyes, cationic indoles, pyronines, phthaleins, oxazines, thiazines, acridines, phenazines, and anthocyanidins, and cationic polymethine dyes and azo and diazopolymethines, styryls, cyanines, hemicyanines, dialkylaminopolyenes, and other related dyes. See Table 2 below for structures for salt isomerism-type photochromic dyes. These photochromic molecules form covalent bonds with a number of agents called bleaching agents because they convert the compounds from colored to colorless form during bond formation. Bleaching agents are diverse and include hydroxide, cyanide, azide, bisulfide, and sulfite compounds, thiocyanate, ferrocyanide, chromate, tetraborate, acetate, nitrite, carbonate, citrate, aluminate, tungstate, molybdate, methoxide, 2-methoxyethoxide, cinnamate, and p-methoxycinnamate salts, and thiols and amines.

TABLE II

Dye Name or Structure; CI Name and Number; Other Names	Nominal Anion[a,b]	Notes Referring to Solvent[b]	λ_{max} (nm)	Solvent
Malachite Green 42000	CN, SO$_3$H, OH	c, cc	622	Ethanol
			617	Water
Helvetia Green 42020	CN	dd, ee		
Basic Blue 1 42025	CN, SO$_3$H	c, h, aa	640	Ethanol
Brilliant Blue			628	Water
Setoglaucine				
Basic Green 1 42040	CN, SO$_3$H	c, d, g, h, m-o, u	633	Ethanol
Brilliant Green			622	Water
Acid Blue 1 42045	CN	dd, ee	628	Ethanol
Xylene Blue VS			636	Water
Patent Blue V				
Alphazurine 2G				
Acid Blue 3 42051	CN	s, dd, ee	632	Water
Brilliant Blue V				
Patent Blue V				
Food Green 3 42053	CN	dd, ee		
FDC Green 3				
Acid Green 6 42075	CN, SO$_3$H	dd, ee	629	Ethanol
Light Green SF Bluish			628	Water
Acid Blue 7 42080	CN	s, dd, ee	628	Ethanol
Xylene Blue AS			633	Water
Patent Blue A				
Acid Green 3 42085	CN, SO$_3$H	dd, hh	626	Ethanol

Name	CI No.	Groups	Refs	λ	Solvent
Acid Blue 9 / Erioglaucine	42090	CN	s, dd, ee	626	Water
Acid Green 5 / Light Green SF Yellowish	42095	CN, SO₃H	dd, ee, hh	634	Ethanol
Acid Green 9 / Erioviridene B	42100	CN, SO₃H	ff-hh	634	Water
Acid Blue 147 / Xylene Cyanol FF	42135	CN	dd, ee	640	Ethanol
				635	Water
Basic Red 9 / Pararosaniline	42500	CN, SO₃H, OH	c, d, g, h, n, o, u, ff-ii	550	Ethanol
				543	Water
Basic Violet 14 / Fuchsin / Magenta	42510	CN, SO₃H	ff-ii	545	Water
Basic Fuchsin	42510B	SO₃H	hh	539	Water
Basic Violet 2 / New Fuchsin / New Magenta	42520	CN, SO₃H	ff-hh	544	Water
Hoffman Violet / Iodine Violet	42530	SO₃H		584	Water
Basic Violet 1 / Methyl Violet	42535	CN, SO₃H	c, e, g, k, u, jj, kk	588	Ethanol
Basic Violet 13 / Methyl Violet 6B	42536	SO₃H		584	Water
Basic Violet 3 / Crystal Violet / Gentian Violet	42555	CN, SO₃H, OH	c, d, g, h, n-p, u, ff ii, kk oo	585	Water
Iodine Green	42556	SO₃H		595	Ethanol

Dye Name or Structure; CI Name and Number; Other Names	Nominal Anion[a,b]	Notes Referring Solvent[b]	Visible Spectrum	
			λ_{max} (nm)	Solvent
Basic Blue 8	42563	CN	aa	594, 538	Water
Victoria Blue 4R					
Acid Blue 13	42571	CN	s, dd, ee	611	Water
Fast Acid Violet 10B					
Acid Blue 75	42576	SO₃H		626	Ethanol
Eriocyanine A				614	Water
Methyl Green	42585	CN	c, j, dd	640	Ethanol
				634	Water
Ethyl Green	42590	CN	s, dd hh		
Basic Violet 4	42600	CN, SO₃H	s	597, 546	Water
Ethyl Violet					
Acid Violet 49	42640	CN, SO₃H	dd, ee	608, 544	Water
Wool Violet 5BN					
Acid Blue 15	42645	SO₃H		554	Water
Brilliant Milling Blue B					
Acid Violet 17	42650	CN, SO₃H	s, dd-hh	591, 548	Ethanol
Acid Violet 6B				592, 539	Water
Wool Violet 4BN					
Formyl Violet					
Acid Violet 5BS Conc.					
Acid Violet 19	42685	CN, SO₃H	ff-hh,	545	Water

| Dye	C.I. No.	Substituents		λ	Solvent	Pages
Acid Fuchsin	42690	SO₃H	*pp-rr*	590	Ethanol	287, 291, 305
Red Violet 5R						281
Acid Blue 22	42755	CN, SO₃H	*dd, ee, hh*	607	Water	281, 284, 286, 292, 293
Aniline Blue						
Soluble Blue						
Solvent Blue 3	42775	SO₃H	*hh*	595 / 590	Ethanol / Methanol	284
Acid Blue 93	42780	CN, SO₃H	*ff, hh*	606 / 586	Ethanol / Water	284, 287
Methyl Blue						
Aurin	43800	CN, OH	*ss, tt*			306, 307
Mordant Blue 3	43820	SO₃H		588	aq. OH⁻	281
Eriochrome Cyanine R						
Acid Green 16	44025	CN	*ee, tt*	638 / 639	Ethanol / Water	303, 307, 310
Naphthalene Green V						
Pontacyl Green NV Extra						
Basic Blue 11	44040	CN, SO₃H	*c, uu*	615, 558	Water	280, 281
Victoria Blue R						
Basic Blue 15	44085	SO₃H		628, 568	Water	281
Night Blue						
Acid Green 50	44090	CN	*ee, tt*	628 / 632	Ethanol / Water	303, 311
Wool Green S						
Kiton Green S Conc.						
Basic Green 3		SO₃H, OH	*hh, pp / rr, ww*	609	9:1 Methanol-Water	284, 286
Sevron Green B						
Brilliant Blue F & R Extra		SO₃H				281
Brilliant Green Sulfonate		CN				288

Dye Name or Structure; CI Name and Number; Other Names	Nominal Anion[a,b]	Notes Referring to Solvent[b]	Visible Spectrum	
			λ_{max} (nm)	Solvent
Hexakis(hydroxyethyl) Pararosaniline	CN		600	Ethanol
New Green	CN		615	Ethanol
Phenolphthalein	CN	xx		
Malachite Green Ethiodide	CN			

| Name	Structure				
Hydroxyalkylated Pararosanilines	C^+ $\left(\right)_3$ N= with $6(CH_2CHOHCH_3)$; $6(CH_2CHOHCH_2Cl)$; $6(CH_2CHOHCH_2OH)$; $3(CH_2CH_2OH) + 3H$; $4(CH_2CH_2OH) + 2H$; $4(CH_2CHOHCH_3) + 2H$	CN	dd		
Hydroxyalkylated New Fuchsins	C^+ $\left(\right)_3$ N= with CH_3, as above	CN	dd		
New Yellow	$(CH_3)_2N-$ $-C^+(C_6H_5)_2$	CN		463	Ethanol
Doebner's Violet	$\left(H_2N- \right)_2 C^+C_6H_5$	CN		575	Ethanol
New Red	$(CH_3)_2N-$ $-C^+-$ $-OCH_3$; C_6H_5	CN		507	Ethanol

Dye Name or Structure; CI Name and Number; Other Names	Nominal Anion[a,b]	Notes Referring to Solvent[b]	Visible Spectrum λmax (nm)	Solvent
Bis(hydroxyethyl) Doebner's Violet	CN		597	Ethanol
"New Magenta"	CN		547	Ethanol
Tetrakis(hydroxyethyl) Doebner's Violet	CN		632	Ethanol
Trichloro Crystal Violet	CN			

Slow Red			

Ethanol

503

574

CN

$(CH_3)_2N$ — C$^+$ — with OCH$_3$, CH$_3$ substituents

(C_3H_7NH) — C$^+$$_3$ — SO$_3$H

$((C_3H_7)_2N)$ — C$^+$$_3$ — SO$_3$H

$((CH_3)_2N)$ — C$^+$$_2$ — OH — SO$_3$H

$((C_2H_5)_2N)$ — C$^+$$_2$ — NHC$_2$H$_5$ — SO$_3$H

$[(ClCH_2CH_2)_2N]$ — C$^+$$_3$ — SO$_3$H

$((C_2H_5)_2N)$ — C$^+$$_2$ — N(C$_2$H$_5$)$_2$, CH$_3$ — SO$_3$H

Dye Name or Structure; CI Name and Number; Other Names	Nominal Anion[a,b]	Notes Referring to Solvent[b]	Visible Spectrum λ_max (nm)	Solvent
(CH₃)₂N—⟨⟩—C⁺(—⟨⟩—OCH₃, NO₂)₂	SO₃H			
(CH₃)₂N—⟨⟩—C⁺(—⟨⟩—OCH₃, NH₂)₂	SO₃H		630	
(CH₃)₂N—⟨⟩—C⁺(—naphthyl)₂	SO₃H		620	
(CH₃)₂N—⟨⟩—C⁺(—⟨⟩—F)(quinoline-N(CH₃)₂)	SO₃H		618	
((CH₃)₂N—⟨⟩)₂C⁺—⟨⟩—⟨⟩—N(CH₃)₂	SO₃H		600	

$((CH_3)_2N-$⟩$_2$ C^+ ⟩$-$⟩$-NHCOCH_3, SO_3H$ 615

$[((CH_3)_2N-$⟩$_2$ C^+-⟩$-$]$_2$ SO_3H 590

[a] Only the cyanide, bisulfite, and hydroxide ions are considered, regardless of the other anions present in the solution.

[b] More detailed descriptions of the compositions of photochromic materials tested are given in Macnair's review [255; tables 1A-4].

[c] Ethanol.

[d] Diethyl ether.

[e] 1,2-Dichloroethane.

[f] 1,1-Dichloroethane, cyclohexane-1,1-dichloroethane, or cyclohexane-1,2-dichloroethane mixtures.

[g] Benzene.

[h] Dimethylsulfoxide, neat and aqueous.

[i] Acetone.

[j] Acetic acid.

[k] Ethyl acetate.

[l] Ethyl bromide.

[m] 2-Methoxyethanol.

[n] Chloroform.

[o] Ethanol with KCN.

[p] Ethanol with KOH.

[q] Carboxylic acids--acetic to stearic; hydrocinnamic acid; ethyl and butyl acid phthalates.

[r] Octadecylnitrile, tributyl phosphate, aniline, 2-(p-tert-butylphenoxy)ethanol, tetraethyleneglycol dimethyl ether, or poly(ethylene glycols).

[s] Amides---formamide to stearamide; methylformamide or methylacetamide; dimethyl- or diethyl-formamide or acetamide.

[t] Three-to-one solutions of cellulose acetate with any of the following five-to-one plasticizer mixtures: Polyethylene Glycol 600 : butyl stearate; Polyethylene Glycol 600 : butyl acetoxystearate, Dowanol EP : butyl stearate, or Dowanol EP : butyl acetoxystearate, Polyethylene Glycol 600 : butyl acetoxystearate, Dowanol EP : butyl acetoxystearate, or Dowanol EP butyl acetoxystearate.

[u] Water containing SO_2.

[v] Water containing bisulfite and papain.

[w] Poly(vinyl alcohol) with dimethylsulfoxide (5 : 1).

x Films, containing residual solvent, cast from the following solutions: ethanol–acetone solutions of vinyl acetate–vinyl alcohol copolymer; aqueous poly(vinyl alcohol); aqueous poly(vinyl pyrrolidone); or aqueous methyl vinylether–maleic acid copolymer.

y Methanol–dioxane with aqueous NH_4HSO_3.

z Paper impregnated with a toluene solution of poly(methyl methacrylate), stearic acid, and 2-(*p-tert*-butylphenoxy)ethanol, then dried.

aa Intramicellar impregnation of cellulose with the following swelling agents: *n*-propylamine, *n*-butylamine, *n*-hexylamine, 2-aminoethanol, dimethylformamide, acetic acid, dimethylsulfoxide, methylacetamide, dimethylacetamide, or formamide.

bb Films cast from an approximately 4 : 3 mixture of a 20 % solution of cellulose acetate butyrate in toluene–ethyl acetate (1 : 1) and triallycyanurate in dioxane.

cc Films cast from a 2 : 1 mixture of a 25 % solution of cellulose acetate butyrate in toluene: ethyl acetate (1 : 1) and the titanium esters of N,N,N', N'-*tetrakis*(2-hydroxypropyl) ethylenediamine.

dd Pure water.

ee Films cast from aqueous gelatin or other hydrocolloids.

ff Dimethylsulfoxide with methanolic KCN.

gg 2-Methoxyethanol with methanolic KCN.

hh Water or aqueous methanol containing bisulfite.

ii Paper impregnated with *m*-dimethoxybenzene, acetonitrile, acetic acid, or phenyl methyl carbinol.

jj Ethanol–benzene.

kk Aqueous ethanol, methanol, aqueous methanol, aqueous acetone, benzene–methanol, carbon tetrachloride–methanol, cyclohexane–methanol, or chloroform–methanol.

ll Films cast from 3 : 1 solutions of cellulose acetate and either Polyethylene Glycol 600$^{@}$ or ethylene glycol phenyl ether as plasticizer.

mm Films, containing residual solvent, cast from solutions of either cellulose acetate in 2-methoxyethanol or poly(vinyl alcohol) in aqueous ethanol.

nn Films, containing residual solvent, cast from solutions of either cellulose acetate butyrate in 2-methoxyethanol or poly(vinyl acetate) in methanol.

oo Ethanol containing ammonia.

pp Aqueous methanol containing NH_4HSO_3, and urease.

qq Aqueous methanol containing NH_4HSO_3, with or without sodium dithionite.

rr Aqueous acid at pH 1.

ss Aqueous ammonia containing KCN.

tt Paper impregnated with aqueous solutions with or without hydrocolloids.

uu 2-Methoxyethanol containing HCl.

vv Aqueous methanol containing NH_4HSO_3, and glucose oxidase.

*ww* 9 : 1 Methanol–water.

xx Aqueous NaOH.

165   X = C=O
168   X = (CH₂)₁,₂

172   R = Na
173   R = H

174

169

$$H^+ \div X^-$$

170 X = CN
171 X = OH

176

179

$(CH_3O \quad)_3 \; C - C \; (\quad NO_2)_3$

177 R = H
178 R = NH$_2$

$((CH_3)_2N \quad)_2 \; \overset{+}{C} - R$

175

$\left[HO_3S \quad \overset{CH_3}{\underset{CH_3}{\bigg|}} \quad \overset{+}{C} \quad NH \quad OCH_3 \right]_2$

- 31 -

Photochromic Polymethine Dyes

α, ω-bis(p-*Dimethylaminophenyl*)*polyenes*

$$(CH_3)_2N-\!\!\!\!\bigcirc\!\!\!\!-\overset{+}{\underset{Ar}{C}}-(CH=\!CH)_n-CH=\!\!\underset{Ar}{C}-\!\!\!\!\bigcirc\!\!\!\!-N(CH_3)_2$$

Ar	n
C_6H_5	0, 1, 2
$4\text{-}(CH_3)_2NC_6H_4$	0, 1, 2
$4\text{-}(CH_3)_2CHC_6H_4$	0, 1, 2, 3, 4
$4\text{-}CH_3OC_6H_4$	0, 1, 2
$4\text{-}C_4H_9OC_6H_4$	0, 1, 2
$3\text{-}CH_3C_6H_4$	1, 2
$4\text{-}t\text{-}C_4H_9C_6H_4$	1, 2
$4\text{-}C_2H_5OC_6H_4$	1, 2
$4\text{-}C_5H_{11}C_6H_4$	1, 2
$4\text{-}FC_6H_4$	1
$4\text{-}F_3CC_6H_4$	1
$2\text{-}(C_6H_5)_2NC_6H_4$	1
$3,4\text{-}H_2N(OCH_3)C_6H_3$	1
2-Naphthyl	1, 2
$4\text{-}ClC_6H_4$	2
$2,4\text{-}Cl_2C_6H_3$	2
1-Naphthyl	2

α, α-bis(p-*dimethylaminophenyl*)*polyenes*

$$(CH_3)_2N\text{—}\langle\ \rangle\text{—}\overset{+}{C}\text{—}\langle\ \rangle\text{—}N(CH_3)_2$$
$$\underset{R}{|}$$

R	R
$-CH=CH-\langle\ \rangle-N(CH_3)_2$	$-CH=C-\langle\ \rangle-N(CH_3)_2$ with $-\langle\ \rangle-CF_3$
$-CH=CCH_3-\langle\ \rangle-N(CH_3)_2$	
$-CH=CH-\langle\ \rangle-N(CH_2CH_2Cl)_2$ with CH_3	$-CH=CH-CH=CH-\langle\ \rangle-N(CH_3)_2$
$-CH=CH-\langle\ \rangle-N(CH_2CH_2Cl)_2$ with Cl	$-CH=CH-\langle\ \rangle-N=N-\langle\ \rangle-OC_2H_5$ with SO_3H
$-CH=C\left(\langle\ \rangle-N(C_2H_5)_2\right)_2$	$-CH=N-N(C_6H_5)_2$
$-CH=C\left[CH=C\left(\langle\ \rangle-N(CH_3)_2\right)_2\right]_2$	$-CH=N-N=C\left(\langle\ \rangle-N(CH_3)_2\right)_2$
	$-N=CH-CH=CH-\langle\ \rangle-N(CH_3)_2$
$-CH=CH-\langle\ \rangle-\overset{+}{C}\left(\langle\ \rangle-N(CH_3)_2\right)_2$	$-CH=\langle\ \rangle=N-\langle\ \rangle-N(CH_3)_2$
$-CH=C-\langle\ \rangle-N(CH_3)_2$ with naphthyl	$-CH=CH-CH=\langle indoline\ \rangle$ with $H_3C\ CH_3$ and $N-CH_3$

Miscellaneous polyenes

$$\left[\begin{array}{c} \text{N}-\text{CH}=\text{CH} \\ \big| \\ \text{O} \end{array} \text{CH}^+ \right]_2$$

$$\begin{array}{c} \text{N} \\ | \\ \text{CH}_3 \end{array} =\text{CH}-\overset{+}{\text{CH}}-\langle \text{C}_6\text{H}_4 \rangle-\text{N}(\text{CH}_3)_2$$

$$(\text{C}_6\text{H}_5)_2\text{N}-\text{CH}=\text{CH}-\overset{+}{\text{CH}}-\langle \rangle-\text{N}(\text{CH}_3)_2$$

$$(\text{CH}_3)_2\text{N}-\langle \rangle-\overset{-}{\text{C}}-\text{CH}=\text{C}-\langle \rangle-\text{C}=\text{CH}-\overset{-}{\text{C}}-\langle \rangle-\text{N}(\text{CH}_3)_2$$
$$\qquad\qquad \text{C}_6\text{H}_5 \quad\quad \text{C}_6\text{H}_5 \quad\quad \text{C}_6\text{H}_5 \quad\quad \text{C}_6\text{H}_5$$

$$\begin{array}{c} \text{C}_6\text{H}_5 \\ \\ \text{H}_5\text{C}_6 \quad \text{S} \end{array} =\text{CH}-\overset{-}{\text{C}}\left(\text{CH}=\text{CH}-\langle \rangle-\text{N}(\text{CH}_3)_2 \right)_2$$

$$\begin{array}{c} \text{H}_3\text{C} \quad \text{CH}_3 \\ \\ \text{N} \\ | \\ \text{CH}_3 \end{array} =\text{CH}\left(\text{CH}=\text{CH} \right)_n\overset{+}{\text{CH}}-\langle \rangle-\text{N}(\text{CH}_3)_2 \qquad (n=0,1)$$

$$\begin{array}{c} \text{H}_3\text{C} \quad \text{CH}_3 \\ \\ \text{N} \\ | \\ \text{CH}_3 \end{array} =\text{CH}-\text{CH}=\text{CH}-\overset{-}{\text{CH}}-\text{CH}= \begin{array}{c} \text{H}_3\text{C} \quad \text{CH}_3 \\ \\ \text{N} \\ | \\ \text{CH}_3 \end{array}$$

Basic Red 13

$$\begin{array}{c} \text{H}_3\text{C} \quad \text{CH}_3 \\ \\ \text{N} \\ | \\ \text{CH}_3 \end{array} =\text{CH}-\overset{-}{\text{CH}}-\langle \rangle-\text{NCH}_3(\text{CH}_2\text{CH}_2\text{Cl})$$

Basic Violet 7

Basic Red 14
Basic Red 15
Basic Violet 15

$$\begin{array}{c} \text{H}_3\text{C} \quad \text{CH}_3 \\ \\ \text{N} \\ | \\ \text{CH}_3 \end{array} =\text{CH}-\overset{-}{\text{CH}}-\langle \rangle-\text{NC}_2\text{H}_5(\text{CH}_2\text{CH}_2\text{Cl})$$

TABLE II (Cont'd)

Structure λ max (mµ)

950

333

400 & 630

TABLE III

PHOTOCHROMIC DYES*

Molecular
Structure

λ max (nm)

412, 550, 870

*These dyes were also useable as photosensitive but non-photochromic dyes in formulations which prevented the usual reversible color formation from taking place.

TABLE III (Cont'd)

Molecular
Structure

- 39 -

TABLE III (Cont'd)

Molecular
Structure

λ max (mμ)

569

CH₃ CH₃ CH₃ CH₃
C—C—C
OCH₃ CH₃O ClO₄⁻

- 41 -

TABLE III (Cont'd)

Molecular Structure	λ_{max} (mμ)
	630

620

580-600

2Cl⁻

N(CH₃)₂

N(CH₃)₂

(CH₃)₂N

(CH₃)₂N

(CH₃)₂N

(CH₃)₂N

TABLE V

PHOTOCHROMIC FORMULATIONS OF REPRESENTATIVE
TRIPHENYLMETHANE DYES

Identification Number*	Structure	Solvent**	Additive	Effect of U.V.	Comments
PC 1011R (CI 42630)		*methyl Cellosolve	KCN in MeOH	Slight photochromism	Light violet.
		DMSO	KCN in MeOH	Good photochromism	Light violet. Major absorption peak 595 my.
		Distilled Water	NaHSO₃	Good photochromism	Dark violet.
PC 1016 (CI 42555)		*methyl Cellosolve	KCN in MeOH	Good photochromism	Violet.
		DMSO	KCN in MeOH	Good photochromism	Violet.
		Distilled Water	NaHSO₃	Good photochromism	Violet. Thermochromic

*The identification numbers are Polacoat numbers and Colour Index numbers. The structures of the dyes were obtained from the Colour Index, Volume 3.

**methyl Cellosolve is a trade name for ethylene glycol monomethyl ether. DMSO refers to Dimethyl Sulfoxide.

TABLE V (Cont'd)

PHOTO-CHROMIC FORMULATIONS OF REPRESENTATIVE
TRIPHENYLMETHANE DYES

Identification Number	Structure	Solvent	Additive	Effect of U.V.	Comments
PC 1023R (CI 42510)		Methyl Cellosolve	KCN in MeOH	Fair photo-chromism	Light red.
		DMSO	KCN in MeOH	Good photo-chromism	Red. Major absorption peak 558 mp.
		Distilled Water	NaHSO$_3$	Good photo-chromism	Positive thermochromism
PC 1024R (CI 42520)		Methyl Cellosolve	KCN in MeOH	Good photo-chromism	Red.
		DMSO	KCN in MeOH	Good photo-chromism	Red. Major absorption peaks 290, 580 mp.
		Distilled Water	NaHSO$_3$	Good photo-chromism	Red. Thermo-chromic

TABLE V (Conc'd)

PHOTOCHROMIC FORMULATIONS OF REPRESENTATIVE TRIPHENYLMETHANE DYES

Identification Number	Structure	Solvent	Additive	Effect of U.V.	Comments
PC 1090 (CI 42590)		Methyl Cellosolve	KCN in MeOH	Good photochroism	Violet. Major absorption peaks 635, 422 and 310 mμ.
		DMSO	KCN in MeOH	Good photochroism	Bright green. Major absorption peaks 625, 426 and 313 mμ.
		Distilled Water	NaHSO$_3$	Good photochroism	Can bleach either violet or colorless depending upon amount of bleach added. Thermochromic
PC 1091 (CI 42755)		Methyl Cellosolve	KCN in MeOH	Good photochroism	Red. Major absorption peaks 300 and 600 mμ.
		DMSO	KCN in MeOH	Good photochroism	Pink.
		Distilled Water	NaHSO$_3$	Good photochroism	Blue. Thermochromic

TABLE V (Cont'd)

PHOTOCHROMIC FORMULATIONS OF REPRESENTATIVE
TRIPHENYLMETHANE DYES

Identification Number	Structure	Solvent	Additive	Effect of U.V.	Comments
PC 1092 (CI 42025)		Methyl Cellosolve	KCN in MeOH	Good photochromism	Green.
		DMSO	KCN in MeOH	Good photochromism	Green. Major absorption peaks 635, 420 and 308 mμ.
		Distilled Water	NaHSO₃	Good photochromism	Green.
PC 1093 (CI 42685)		Methyl Cellosolve	KCN in MeOH	Fair photochromism	Pink
		DMSO	KCN in MeOH	Good photochromism	Light red. Major absorption peaks 550 and 290 mμ.
		Distilled Water	NaHSO₃	Good photochromism	Red. Thermochromic

TABLE V (Cont'd)

PHOTOCHROMIC FORMULATIONS OF REPRESENTATIVE
TRIPHENYLMETHANE DYES

| Identification Number	Structure	Solvent	Additive	Effect of U.V.	Comments
PC 1094 (CI 42500)		Methyl Cellosolve	KCN in MeOH	Fair photo-chromism	Light red.
		DMSO	KCN in MeOH	Good photo-chromism	Light red. Major absorption peaks 550 and 294 mµ.
		Distilled Water	NaHSO₃	Good photo-chromism	Red.
PC 1093 (CI 42500)		Methyl Cellosolve	KCN in MeOH	Poor photo-chromism	Light orange.
		DMSO	KCN in MeOH	Poor photo-chromism	Light orange. Major absorption peak 560 mµ.
		Distilled Water	NaHSO₃	Good photo-chromism	Dye is very slightly soluble.

TABLE V (Cont'd)

PHOTOCHROMIC FORMULATIONS OF REPRESENTATIVE
TRIPHENYLMETHANE DYES

Identification Number	Structure	Solvent	Additive	Effect of U.V.	Comments
PC 1104 (CI 42100)		Methyl Cellosolve	KCN in MeOH	Poor photo-chromism	Light green.
		DMSO	KCN in MeOH	Poor photo-chromism	Light green.
		Distilled Water	NaHSO₃	Good photo-chromism	Green.
PC 1106 (CI 42095)		Methyl Cellosolve	KCN in MeOH	No photo-chromism	
		DMSO	KCN in MeOH	No photo-chromism	
		Distilled Water	NaHSO₃	Good photo-chromism	Green.

TABLE V (Cont'd)

PHOTOCHROMIC FORMULATIONS OF REPRESENTATIVE
TRIPHENYLMETHANE DYES

Identification Number	Structure	Solvent	Additive	Effect of U.V.	Comments
PC 1113 (CI 42085)		Methyl Cellosolve	KCN in MeOH	Fair photochromism	Light green.
		DMSO	KCN in MeOH	Good photochromism	Green. Major absorption peaks 635 and 430 mμ.
		Distilled Water	NaHSO$_3$	Good photochromism	Green.
PC 1113 (CI 42500)		Methyl Cellosolve	KCN in MeOH	Fair photochromism	Light red.
		DMSO	KCN in MeOH	Good photochromism	Red. Major absorption peaks 550 and 293 mμ.
		Distilled Water	NaHSO$_3$	Good photochromism	Red.

SALT-ISOMERISM TYPE PHOTOTROPIC DYES

Night Blue

Victoria Blue R


Brilliant Milling Blue B

Brilliant Blue F & R Ex.

Eriocyanine A

Methyl Blue

Aniline Blue

Eriochrome Cyanine R


Methyl Violet 6B

Iodine Green

Aniline Blue


Wool Violet 5 BN

- 55 -

Wool Violet 4 EM

Light Green SF
Yellowish

- 56 -

Iodine Violet

Methyl Violet

Crystal Violet

- 57 -

Ethyl Violet

Acid Green L Extra

- 58 -

Erioviridene B

Light Green SF

- 59 -

Victoria Green
(Malachite Green)

Red-Violet 5R

Brilliant Green "B"

Di-[4(N,N-diethylamine)phenyl]-[4-(N,N-diethyl-
amine-2-methyl) phenyl] methyl carbonium

Tri-[4(N,N-dipropylamino)phenyl] methyl carbonium

Di-[4(N,N-diethylamino)phenyl]-[4(ethylamino)-
phenyl] methyl carbonium

Di-[4(N,N-diethylamino)phenyl]-[4(N,N-diethyl-
amino)naphthyl] methyl carbonium

Di-[4(N,N-dimethylamino)phenyl]-[4(hydroxy)phenyl]
methyl carbonium

Tri-[4(N-propylamino)phenyl] methyl carbonium

Hectolene Blue DS-1398

Hectolene Blue DS-1823

Sevron Brilliant Red 4G

Di-[4(N,N-dimethylamino)phenyl]-[4(hydroxy)phenyl]
methyl carbonium

Tri-[4(N-propylamino)phenyl] methyl carbonium

- 63 -

Hectolene Blue DS-1398

Hectolene Blue DS-1823

Sevron Brilliant Red 4G

Genacryl Red 6B

Genacryl Pink G

Sevron Brilliant - Red B

Sevron Brilliant - Red 3B

1,5-bis-[4(N,N-dimethylamino)phenyl]-1,5-bis-
(phenyl)divinyl carbonium trifluoroacetate

1,1,3,3-tetrakis[4(N,N-dimethylamino)phenyl]
vinyl carbonium perchlorate

1,5-bis-[4(N,N-dimehtylamino)phenyl]-1,5-bis-
(phenyl) divinyl carbonium p-toluenesulfonate

1,7-bis-[4(N,N-dimethylamino)phenyl]-1,7-bis-(2,4-dichlorophenyl) trivinyl carbonium per-chlorate

Di-[4(N,N-dimethylamino)phenyl vinyl]-[2,4-di-phenyl-6-methane thiopyran] methyl carbonium perchlorate

- 66 -

1,7-bis-[4-(N,N-dimethylamino)phenyl]-1,7-bis-
(4-chlorophenyl) trivinyl carbonium trifluoro-
acetate

1,1,3-tris-[4-(N,N-dimethylamino)phenyl] divinyl
carbonium perchlorate

1,1,7,7-tetrakis-[4-(N,N-dimethylamino)phenyl]
trivinyl carbonium perchlorate

1,3-bis-[4-(N,N-dimethylamino)phenyl]-1,3-bis-
(phenyl) vinyl carbonium perchlorate

- 68 -

1,1,5,5-tetrakis-[4-(N,N-diemthylamino)phenyl]
divinyl carbonium perchlorate

1,5-bis-[4-(N,N-dimethylamino)phenyl]-1,5-bis-
(phenyl) divinyl carbonium perchlorate

- 69 -

1,7-bis-[4-(N,N-dimethylamino)phenyl]-1,7-bis-
(phenyl) trivinyl carbonium trifluoroacetate

1,1,5-tris-[4-(N,N-dimethylamino)phenyl] divinyl
carbonium perchlorate

1(1,3,3-trimethyl   indoline)-2-[4-(N,N-dimethyl-
amino)phenyl] ethylene carbonium perchlorate

1(1,3,3-trimethyl   indoline)-4-[4-(N,N-dimethyl-
amino)phenyl] butylene carbonium perchlorate

1,1,3,3-tetrakis-[4(N,N-diethylamino)phenyl]
vinyl carbonium perchlorate

1,1-bis-[4-(N,N-diethylamino)phenyl]-3,3-bis-
[4-(N,N-dimethylamino)phenyl] vinyl carbonium
perchlorate

- 72 -

1,1,5,5-tetrakis-[4-(N,N-diethylamino)phenyl]
divinyl carbonium perchlorate

1,1-bis-[4-(N,N-dimethylamino)phenyl]-3-[4-(amino)
phenyl]-3-methylvinyl carbonium perchlorate

- 73 -

Tris-[1,1-bis-[4(N,N-dimethylamino)phenyl]
ethylene] methyl carbonium perchlorate

Tris-[1,1-bis-[4-(N,N-diethylamino)phenyl]
ethylene] methyl carbonium perchlorate

1,1,5-tris-[4-(N,N-dimethylamino)phenyl] divinyl carbonium perchlorate

N[4-(N,N-dimethylamino) cinnamylidene] auramine

- 75 -

1,1-bis-[4-(N,N-dimethylamino)phenyl-3,4-bis-
(phenyl)]-3,4-diazo butene carbonium

1,1,5,5-tetrakis-[4-(N,N-dimethylamino)phenyl]-
2,3-diazo pentene carbonium

N-(N',N'-dimethylamino cinnamylidene)-N,N-diphenyl ammonium

Azo Polymethines

Dyes of the general structural type

Photochromic diazopolymethines

1,1,5,5-tetrakis-[4-(N,Np-dimethylamino)phenyl]-
2,3-diazo pentene carbonium

1,1-bis-[4-(N,N-dimethylamino)phenyl-3,4-bis-
(phenyl)]-3,4-diazo butene carbonium

- 79 -

The drug functionality, C, includes any molecule which exhibits bleaching behavior with the B functionality and has an increased therapeutic effect or therapeutic ratio as a consequence of its delivery as part of a Luminide agent. For example, Foscarnet, a viral reverse transcriptase inhibitor possesses both a carboxylate and phosphate group which will bleach photochromic compounds; 4-bromocrotonyl-CoA, an acetoacetyl -CoA thiolase inhibitor, possesses a thiol group which will bleach photochromic compounds; L-3-iodo-α- methyltyrosine, a tyrosine hydroxylase inhibitor, possesses a carboxylate group which will bleach photochromic compounds, and captopril, an antihypertensive pharmaceutical, possesses both a sulfide and carboxylate group which will bleach photochromic compounds. Furthermore, the pharmacokinetics and/or pharmacodynamics of these agents are altered via delivery to the site of action by way of a luminide agent such that the therapeutic effect or therapeutic ratio is enhanced.

Other drugs which are not inherently photochromic bleaches in that they lack a nucleophilic group which will form a reversible covalent bond with the B functionality can be derivatized with a known bleaching nucleophilic group such as cinnamate, sulfite, phosphate, carboxylate, thiol, or amine group to transform them into bleaching agents of the B functionality such as a cationic dye. See Table 3 below for the structure of a exemplary drug molecules.

Table 3.   Representative Drug Molecules.

Name	Structure

Captopril

Prostaglandin E_2

2,3-dichloro-α-methylbenzylamine

3'-deoxy-S-adenosyl-L-homocysteine

Sinefungin

3,5-diiodo-4-hydroxybenzoic acid

6,6'-dithiobis (9-B-D-ribofuranosylpurine)

γ-aminobutyric acid

$$H_2NCH_2CH_2CH_2COOH$$

- 82 -

Gabaculine

N-(5'-phosphopyridoxyl)-4-aminobutyric acid

4-amino-hex-5-enoic acid

$$CH_2=CHCHCH_2CH_2COOH$$
$$NH_2$$

Baclofen

Adenosine

3-hydroxy-3-methylglutarate

$$CH_3CH_2\overset{\overset{\displaystyle OH}{|}}{C}CH_2COOH$$
$$\underset{\displaystyle CH_3}{|}$$

Compactin

But-3-ynoyl-CoA

Suramin

L-3-iodotyrosine

L-3-iodo-α-methyltyrosine

Disodium cromoglycate

Adenosine 3',5'-cyclic monophosphate

D,L-B-(5-hydroxy-3-indolyl)-α-hydrazinopropionic acid

D,L-α-hydrazino-α-methyldopa

α-methyldopa

5-(3,4-dihydroxycinnamoyl)salicylic acid

N-(phosphonacetyl)-L-aspartate

P-glycolohydroxamate

$$O=P-O-CH_2-C=N-OH$$

5-(p-sulfamylphenylazo)salicylic acid

Coformycin

Formycin B

- 88 -

Thioinosinate

Phosphonoformate

Phosphonoacetate

Ridavirin

- 89 -

Sotalol

$$CH_3\overset{\overset{O}{\|}}{\underset{\underset{O}{\|}}{S}}NH-\bigcirc\!\!\!-\overset{\overset{OH}{|}}{\underset{|}{C}}HCH_2NHCH(CH_3)_2$$

Cimetidine

$$\begin{array}{c} CH_3 \quad CH_2SCH_2CH_2N{=}C\overset{NHCH_3}{\underset{NHC{\equiv}N}{}} \\ HN{-}{=}N \end{array}$$

Fuscaric acid

$$\begin{array}{c} \overset{COOH}{N} \\ CH_3CH_2CH_2CH_2 \end{array}$$

2-mercaptoethylamine

$$HSCH_2CH_2NH_3{}^+$$

Mimosine

$$\text{CH}_2\text{CHCOOH}$$

(with NH₂ on the CHCOOH carbon: $\text{CH}_2\overset{\text{NH}_2}{\text{CHCOOH}}$, attached to N of the pyridinone ring bearing OH and =O)

U-7130

$$\text{C}_6\text{H}_5\text{-NH-}\overset{\text{S}}{\text{C}}\text{-CH}_2\text{COOH}$$

Iproniazid

(pyridine ring with OH, bearing $-\overset{\text{O}}{\text{C}}-\text{NHNHCH(CH}_3)_2$)

Trans-4-aminocrotonic acid

$$\text{H}_2\text{NCH}_2\text{CH}=\text{CHCOOH}$$

NSD 1055

(benzene ring with HO, Br, and CH_2ONH_2 substituents)

Nicotinic acid

Kynurenic acid

Lentysine

Orotic acid

- 92 -

Polyoxin D

Cephalosporin

Penicillin

The electron transfer functionality, D, includes molecules which undergo a redox reaction which transfers electrons between the electron carriers and the A functionality where a redox reaction of A results in its activation to an excited energy state. The D functionality can be a natural electron carrier such as ubiquinone or a synthetic electron carrier such as methylene blue, phenazine methosulfate, or 2,6-dichlorophenolindophenol. Structures of electron transfer molecules appear below in Table 4.

- 94 -

Table 4.   Representative Electron Transfer Molecules.
         Name   Structure

Methylene Blue

Ubiquinone

2, 6 - dichlorophenolindophenol

Phenazine methosulfate

Ferricyanide

A Representative Luminide

    A representative luminide is the product of the
covalent linkage of the polymethine dye with a
bleaching drug such as Foscarnet and with a
chemiluminescent reactive molecule such as luminol.
This conjugate represents a molecule which releases
Foscarnet in the presence of oxygen free radicals.
The energy of the reaction of luminol with oxygen
radicals undergoes intramolecular electronic energy
transfer by radiative and nonradiative mechanisms.
The latter dominate and include coulombic
interactions, dipole-dipole resonance, and exchange
interaction. These processes increase the quantum
yield for drug release above that which would be
produced by luminescence transfer alone. For
example, Forster, in a quantum mechanical treatment
of resonance transfer, in the region of spectral
overlap involving allowed transitions of two well
separated molecules has only considered dipole-dipole
interactions in deriving an experimentally verified
formula which predicts a distance of 5-10 nm as the
distance at which transfer and spontaneous decay of
the excited donor are equally probable. The formula
predicts the transfer probability is inversely
proportional to the separation distance raised to the
sixth power. However, the donor and accepter
functionalities of a Luminide are covalently linked;
thus, since the separation distance is of the order
of angstroms, the transfer probability is great. In
fact, the efficiency of transfer has been studied in
certain molecules which consist of two independent
chromophores separated by one or more saturated
bonds. In such cases, energy transfer over large

- 97 -

distances has been observed to be in agreement with predictions from Forster's Theory.

The Luminides can be prepared by known reactions where necessary, appropriate derivatives of the subunits are formed before coupling.

Representative examples of appropriate derivatization and coupling reactions are given in the following examples, illustrating the preparation of representative Luminides. These examples are not to be taken as an exhaustive listing, but only illustrative of the possibilities according to the present invention.

Representative Luminides with
Outline of Synthetic Pathway.

Luminides synthesis involves the chemical joining of three or four functionalities. A representative luminide of three functionalities comprises an energy donor molecule such as a chemiluminescent molecule, an energy acceptor molecule such as a photochromic molecule, and a drug. A representative luminide of four functionalities comprises the mentioned three functionalities and also an electron transfer functionality which can undergo an oxidation reduction reaction.

A three group Luminde can be formed by condensing a photochromic dye functionalized as an acid chloride with a chemiluminescent molecule possessing an alcoholic or amino group to form an ester or amide. The luminide pharmaceutical is then formed by addition of the drug bleaching agent. An exemplary pathway of this type appears in example 1.

Alternatively, the chemiluminescent or/and electron transfer functionality can be linked to the

energy acceptor functionality by formation of an
ester or amide where the former
functionality/functionalities is/are an acid halide
as demonstrated in example 15.

Also, functionalities of the electron transfer
and energy donor type can be linked to the energy
acceptor part by an acylation reaction as
demonstrated in examples 2, 3 and 8; by nucleophillic
substitution as demonstrated in examples 4, 5, 6, 7,
9, 10, 12 and 17; by a carbanion mechanism as
demonstrated in example 11; by a Grignard reaction as
demonstrated in example 14, by a tosylate mechanism
as demonstrated in example 13, or by a Wittig
reaction as demonstrated in example 16. Similar
reaction pathways can be used to link
chemiluminescent molecules to energy donor
molecules. The list of examples of reaction pathways
is intended to be examplary and other pathways can be
devised by one skilled in the art. Furthermore, only
a representative number of luminides are shown and a
vast number of other novel luminides can be made by
one skilled in the art following the guidelines
herein disclosed.

And, the disclosed exemplary luminides, and
components: chemiluminescent molecules, photochromic
molecules, energy transfer molecules, and drug
molecules can be modified to further candidate
components by addition of functional groups by one
skilled in the art. Representitive groups include
aklyl, cycloalkl, alkoxycarbonyl, cyano, carbamoyl,
heterocyclic rings containing C, O, N, S, sulfo,
sulfamoyl, alkoxysulfonyl, phosphono, hydroxyl,
halogen, alkoxy, alkylthiol, acyloxy, aryl, alkenyl,
aliphatic, acyl, carboxyl, amino, cyanoalkoxy,
diazonium, carboxyalkylcarboxamido, alkenyl, thio,

cyanoalkoxycarbonyl, carbamoylalkoxycarbonyl, alkoxy
carbonylamino,   cyanoalkylamino,   alkoxycarbonyl-
alkylamino,   sulfoaklylamino,   alkylsulfamoylaklyl-
amino, oxido, hydroxy alkyl, carboxy alkylcarbonyl-
oxy,   cyanoalkyl,   carbonyloxy,   carboxyalkylthio,
arylamino, heteroarylamino, alkoxycarbonyl, alkyl-
carbonyloxy,   carboxyalkoxy,   cyanoalkoxy,   alkoxy-
carbonylalkoxy,   carbamoylalkoxy,   carbamoylalkyl
carbonyloxy,   sulfoalkoxy,   nitro,   alkoxyaryl,
halogenaryl, amino aryl, alkylaminoaryl, tolyl,
alkenylaryl, allylaryl, alkenyloxyaryl, allyloxyaryl,
allyloxyaryl, cyanoaryl, carbamoylaryl, carboxyaryl,
alkoxycarbonylaryl, alkylcarbonyoxyaryl, sulfoaryl,
alkoxysulfoaryl, sulfamoylaryl, and nitroaryl.

- 100 -

EXPERIMENTAL SECTION I

Synthesis

Synthesis of MTL 7-3, and MTL J-1

Step A: Preparation   of   p-N,N-dimethylaminobenzoyl chloride

In a round bottom flask fitted with a reflux condenser is placed 4 g of p-dimethylaminobenzoic acid and 8 ml of oxalylchloride. The evolution of gas starts immediately and the spontaneous reaction is run at room temperature for 15 minutes. 8 ml of toluene is added and and the mixture is heated to gentle reflux for one hour. The reaction mixture is then distilled to dryness under reduced pressure to produce a blue-green solid which is washed with ether and dried on a watch glass.

Step B: Preparation of p-dimethylaminobenzanilide

A solution of 0.95 g of aniline in 10 ml of dry ether containing 2.2 g of K_2CO_3 was heated to reflux temperature. To the refluxing mixture 2 g of p-dimethylaminobenzoyl chloride was added as a powder slowly through the condenser port. The reaction was refluxed for 1.5 hours and the ether distilled off. Cold water was added to the residue and the p-dimethylaminobenzanilide collected by filtration. Yield 1.51 g orange-red powder. Anilide functionality confirmed by IR.

Step C: Preparation of
p-N,N dimethyl-p-N-ethyl-N-2-chloroethylbenzophenone.

1.5 g of dry, powdered p-dimethylbenzanilide, 2.4 g
of N-ethyl-N-2-chloroethylaniline, and 1.3 ml of
phosphorus oxychloride were mixed in a 25 ml 2-necked
flask, fitted with a thermometer immersed in the
reation mixture and a reflux condenser having a
$CaCl_2$ drying tube on top. The reaction was warmed
slowly until an exothermic reaction occured. The
temperature was maintained at less than $100^{\circ}C$ by
periodic immersion of the flask in ice water. The
reaction was then maintained at $95^{\circ}C$ for one hour
to yield a dark green liquid. The reaction mixture
was then hydrolyzed in a 150 ml beaker with the
addition of a solution of 1.36 ml of concentrated HCl
to 10.4 ml of distilled H_2O. The beaker was
covered with a watch glass and heated on a hot water
bath for 1.5 hours to yield a green-yellow solution.
10:1 cold water was added to the hydrolyzed mixture
to form a brilliant purple solution which was
filtered. The filtered product was dissolved in a
minimum volume of ethanol, and twice the volume of
cold H_2O was added. The ketone was then extracted
in an equal volume of chloroform which was removed by
distillation to dryness under reduced pressure.
Brilliant purple solid product. Ketone confirmed by
IR and NMR.

Step D: Preparation of
1-(4-N,N-dimethylaminophenyl)-1-(4-N-ethyl-N-2-chloroet
hylphenyl) ethylene.

One ml of a 3 molar etherial solution of magnesium bromide was evaporated almost to dryness under reduced pressure in a 50 ml three necked flask equipped with a thermometer and nitrogen sparger. The grey moist solution was suspended in 1.3 ml of dry benzene. The flask was then equipped for refluxing by the addition of a condenser fitted with a $CaCl_2$ drying tube and an addition funnel. 0.017 moles of the ketone dissolved in 4.4 ml of boiling benzene was then placed in an addition funnel and added dropwise to the warmed methyl magnesium bromide-benzene slurry over a half hour period. The resulting solution was refluxed for one hour. The completion of the reaction was evident by the color change of the solution from brilliant purple to blue. The reaction mixture was cooled to room temperature, and 0.785 ml of saturated NH_4Cl was cautiously added. Additional NH_4Cl was added until two layers were apparent with the blue alcohol product in the bottom H_2O layer. 1.7×10^{-3} g of p-toluenesulphonic acid was added, and the solution was boiled on a water bath with the addition of benzene until the evaporation of H_2O was complete and only the benzene layer remained. The acid contained in the reaction mixture was then removed by the addition of 0.73×10^{-3} g of sodium bicarbonate. The solvent was reduced to dryness under reduced pressure to yield light blue crystals.

- 106 -

Step E: Preparation   of   a   perchlorate   of
1,5-di-(p-N-2-chloroethyl-N-ethylaminophenyl)-1,5-bis-(
p-N,N-dimethylaniline)-1,3-pentadiene.

$(CH_3)_2N$—

CH_3CH_2
$ClCH_2CH_2$—N—

$C=CH_2$

$+$ $HC(OC_2H_5)_3$ $\xrightarrow{\text{Acetic Anhydride}}$

$HClO_4$

$(CH_3)_2N$—

CH_3CH_2
N
$ClCH_2CH_2$

$C=CH-CH=CH-C$

$\overset{+}{N}(CH_3)_2$

CH_3CH_2
N
$ClCH_2CH_2$

ClO_4^-

- 107 -

A mixture of 8.7 x 10^{-4} moles of 1-(4-N,N-dimethylaminophenyl)-1-(4-N-2-chloroethyl-N-et hylaminophe-nyl)ethylene, 0.13 ml of ethyl orthoformate, and 0.39 ml of acetic anhydride was treated with a solution of 0.035 ml of 72 percent perchloric acid and 0.35 ml of acetic acid previouly cooled to 0°C. The resulting mixture was allowed to stand at room temperature for 8 days, after which time it was treated with 0.22 ml of ether and kept an additional day at room temperature. The condensation product was washed with acetic acid, ethanol, and ether. The pale blue-green crystals were dissolved in a minimum volume of warm dry ethanol. The solution was centrifuged to pellet a white precipitate. The dark blue supernatant solution was removed and distilled to dryness under reduced pressure. The blue crystals where placed on watch glass and placed in the dark. The structure of the condensation compound was confirmed by IR and NMR.

Step F: Preparation of
1,5-di-(p-N-2-(N-(4-aminobutyl)-N-ethyl
isolminol)-N-ethylaminophenyl)-1,5-bis-(p-N,N-dimethyla
niline)-1,3-pentadiene.

$$+$$

$$\rightarrow$$

Pyridinium perchlorate

- 110 -

5 mg (1.8 x 10^{-5} moles) of N-(4-aminobutyl)-N-ethylisoluminol was suspended in 0.1 ml of pyridine in a small test tube. 30 mg (3.6 x 10^{-5} moles) of the pentadiene was dissolved in 0.5 ml of pyridine and 0.25 ml of DMSO. This latter solution was added dropwise to the former while vigorously stirring at room temperature initially then with intermittant imersion in a water bath at 35°C. The isoluminol which was only slightly soluble in pyridine went into solution as the reaction progressed. The reaction mixture was stirred and intermittantly immersed in the water bath at 35°C until the reaction was complete. This reaction and all subsequent reactions were protected from direct light.

- 111 -

Step G: Preparation   of   Luminide,   MTL   7-3
(2,6-di-(p-N-2-(N-(4-aminobutyl)-N-ethylisoluminol)-N-e
thylamino-
phenyl)-2,6-bis-(p-N,N-dimethylanilino)-3,5-hexadinenit
rile).

- 113 -

5 mg of solid KCN and 1 ml of distilled H_2O were added to the blue-grey solution of 1,5-di-(p-N-2-(N-(4-aminobutyl)-N-ethylisoluminol)-N-ethylaminophe-nyl)-1,5-bis-(p-N,N-dimethylanilino)-1,3-pentadiene in pyridine/DMSO solvent. The solution was acidified by addition of sulphuric acid and the evolving HCN gas was removed by evaporating the solvent to dryness under reduced pressure. The pale green crystals were redissolved in DMSO to yield a pale green liquid. IR and NMR confirmed the structure.

Step H: Preparation of Luminide MTL J-1

(5-phosphonoformate-1,5-di-(p-N-2-(N-(4-aminobutyl)
-N-ethylisoluminol)-N-ethylaminophenyl)-1,5-bis-
(p-N,N-dimethylaniline)-1,3-pentadiene).

MTL J-1 was prepared by the equimolar addition
of disodium phosphonoformate dissolved in H_2O to a
DMSO   solution   of
1,5-di-(p-N-2-(N-(4-aminobutyl)-N-ethylisoluminol)
-N-ethylaminophenyl)-1,5-bis(p-N,N-dimethylaniline)-1,3
-pentadiene
such that the final solvent was 4:3 DMSO/H_2O. The
reaction mixture was protected from light, and the
colorless reaction product solution was packaged in
light protecting vials and refrigerated at $4^{O}C$.

Methods of synthesis of triphenylmethane dyes
appear in Appendix I.

Methods of synthesis of polymethine dyes appear
in Appendix II.

Methods of synthesis of azo and diazopolymethine
dyes appear in Appendix III and IV, respectively.

Methods of synthesis of quaternary ammonium salt
poly methines appear in Appendix V.

Methods of synthesis of the intermediates,
tetramethylortho carbonate and substituted ethylenes
appear in Appendix VI.

Methods of synthesis of indoline based dyes
appear in Appendix VII.

Methods of synthesis of dyes with more than one
chromophore appear in Appendix VIII.

Methods of forming a leucocyanide appear in
Appendix IX.

- 117 -

Further Exemplary Material

Example 1.

    The compound shown as formula 6 is prepared as
follows:

- 118 -

- 119 -

+

→

(6)

- 120 -

Phenolphthalein is converted to the corresponding acid chloride by treatment with oxalyl chloride. The acid chloride is reacted with chloromethylamine to form the corresponding amide which is in turn reacted with a dioxetan such as compound 4 to give adduct 5 where compound 4 is prepared from the appropriate starting dioxtene by a method described by Schaap. The adduct 5 is converted to the final product by treatment with Captopril.

- 121 - ·>

Example 2.

The compound shown as formula 10 is prepared as follows:

(9)

(10)

Compound 7 is acylated with an acridinium ester such as compound 8 to give adduct 9 which is treated with prostaglandin E_2 to give the final product 10.

Example 3.

The compound shown as formula 14 is prepared as follows:

(1 1)

+

(12)

AlCl$_3$

→

(13)

(14)

- 128 -

Compound 11 is acylated with a biacridinium derivative such as 12 to give adduct 13 which is treated with 5-(p-sulfamylphenylazo) salicylic acid to give the final product 14.

Example 4.

The compound shown as product 18 is prepared as follows:

(15)

(16)

(17)

(18)

- 130 -

Compound 15 is reacted with the carboxylate 16 to form the ester 17 where 16 is formed by linking an oxidation reduction agent such as a derivative of 2, 6-dichloro phenolindophenol with a dioxene carboxylate derivative. The ester 17 is reacted with p-glycolohydroxamate to give the final product.

Example 5.

The compound shown as formula 22 is prepared as follows:

(19)

(20)

- 132 -

Compound 19 which is formed using an appropriately substituted aniline is reacted with adduct 20 to give adduct 21 where adduct 20 is formed by alkylation of the aromatic ring of an active oxalate derivative with a molecule which can accept electrons via electron transport. Adduct 21 is treated with Baclofen to form the product 22.

Example 6.

The compound shown as formula 26 is prepared as follows:

(23)

+

(24) →

(25)

(26)

- 135 -

Compound 23 is prepared with the appropriately substituted ethoxy groups which is then reacted with a phthalhydrazide such as 24 to form adduct 25. The final product 26 is formed by treatment of adduct 25 with γ-aminobutyric acid.

Example 7.

    The compound shown as formula 30 is prepared as follows:

(27)

(28)

(30)

Compound 27 is reacted with adduct 28 which is formed by akylation of an active oxalate by a methylene blue derivative.

The product adduct 29 is treated with adenosine 3', 5'-cyclic monophosphate to yield the final product 30.

Example 8.

The compound shown as formula 34 is prepared as follows:

(31)

(32)

(33)

(34)

- 142 -

Compound 31 is acylated with an active oxalate such as 32 to yield adduct 33. Adduct 33 is treated with Ridavirin to yield the final product 34.

Example 9.

The compound shown as formula 38 is prepared as follows:

(35)

(36)

(37)

(38)

- 145 -

Compound 35 is reacted with an alkyl halide derivatived active oxalate such as 36 to give adduct 37 which is treated with phosphonoacetate to give the final product 38.

Example 10.

The compound shown as formula 42 is prepared as follows:

(39)

(40)

$N(CH_3)_2$ $N(CH_3)_2$

$CH=CH$ $CH=CH$

CH $\overset{+}{C}$ CH

$=CH$

S

CH_2

CH_2NHCH_2

CH_3

N

CH_3

CH_3

N

O

O

(41)

- 147 -

(42)

- 148 -

Compound 39 is prepared using the proper chloromethyl substituted benzene and reacted with a dioxene derivative such as 40 to yield adduct 41. Adduct 41 is treated with U-7130 to give the final product 42.

Example 11.

The compound shown as formula 47 is prepared as follows:

$+$

$\xrightarrow[-H_2O]{H^+}$

(43)

(44)

(45)

(46)

- 152 -

(47)

Compound 43 is dehydrated and treated with an indole ketone derivative dioxene such as 44 to give intermediate adduct 45 which is hydrolyzed to the ketone adduct 46. Adduct 46 is treated with N-(phosphonacetyl)-L-asparate to yield the final product 47.

Example 12.

The compound shown as formula 51 is prepared as follows:

(48)

(49)

(50)

- 155 -

(5 1)

- 156 -

Compound 48 is prepared from the proper chloromethyl naphthalene and reacted with a phthalhydrazide such as 49 to give adduct 50 which is reacted with trans-4-aminocrotonic acid to give the final product 51.

Example 13.

The compound shown as formula 56 is prepared as follows:

$(HOCH_2CH_2)_2N$—⟨⟩—$\overset{+}{C}$—⟨⟩—$N(CH_2CH_2OH)_2$

(52)

$N(CH_2CH_2OH)_2$

+ CH_3—⟨⟩—$\overset{O}{\underset{O}{\overset{\|}{\underset{\|}{S}}}}Cl$ →

(53)

(54)

- 158 -

(55)

+

(56)

- 160 -

Compound 52 is reacted with p-toluene sulfonyl chloride to give tosylate adduct 52 which is reacted with an active oxamide that has an alcoholic function such as 54 to give ether adduct 55. The adduct 55 is reacted with compactin to give the final product 56.

Example 14.

The compound shown as formula 62 is prepared as follows:

(57)

(58)

(59)

(60)

$$+ \quad CH_2=CHCHCH_2CH_2COOH$$
$$\underset{NH_2}{|}$$

(6 1)

$\longrightarrow$

(6 2)

Compound 57 is reacted with Mg to form the Grignard reagent 58 which is reacted with a dioxene indole derivative with an aldehyde or ketone functionality such as 59 to give the alcohol 60. Adduct 60 is reacted with 4-amino-hex-5-enoic acid, 61, to give the final product 62.

Example 15.

The compound shown as formula 67 is prepared as follows:

(63)

(64)

(65)

(66)

(67)

The compound 63 is reacted with an acid halide such as 64 to give adduct 65. The acid halide 64 is prepared from the corresponding acid by reaction with oxalyl chloride. The original acid is prepared by reacting a phenazine possessing an alkyl halide and a carboxylic acid function with an indole derivative that has a amino group. The adduct amide 65 is reacted with but-3-ynoyl-CoA, 66, to give the final product 67.

Example 16.

The compound shown as formula 71 is prepared as follows:

$$(CH_3)_2N - \text{C}^+ - N(CH_3)_2$$

with pendant phenyl group bearing $HC=O$

+

(68)

(69)

(70)

(7 1)

- 171 -

The aldehyde compound 68 is reacted with a
phosphonium ylid of a ubiquinone nucleus linked to a
indole dioxene derivative such as 69 to form adduct
ethylene 70. (The ylid 69 is formed by an acylation
reaction of an indole derivative dioxene with a
ubiquinone adduct followed by reaction with
triphenylphosphine.) The adduct 70 is reacted with
DL-2-hydrazino-α-methyldopa to form the final
product 71.

Example 17.

The compound shown as formula 76 is prepared as follows:

- 173 -

(74)

(75)

(76)

The alkylchloride 72 is reacted with alkyl amine Lophine derivate 73 to yeild adduct 74 which is reacted with disodium cromoglycate, 75, to form the final product 76.

Preparations and Routes of Administration of Luminides

Luminides can be administered orally, intramuscularly or intraveneously.

Medicinal formulations which contain one or more Luminide compounds as the active compound can be prepared by mixing the Luminide (s) with one or more pharmacologically acceptable excipients or diluents, such as, for example, fillers, emulsifiers, lubricants, flavor correcting agents, dyestuffs or buffer substances, and converting the mixture into a suitable galenic formulation form, such as, for example, tablets, dragees, capsules or a solution or suspension suitable for parenteral administration. Examples of excipients or diluents which may be mentioned are tragacanth, lactose, talc, agar - agar, polyglycols, ethanol and water. Suspensions or solution in water can preferably be used for parenteral administration.

Also, Luminides can be prepared as sterile lyophilized powder to which a sterile solvent such as water or dimethylsulfoxide is added. Luminides are also prepared as a sterile lyophilized powder containing deoxycholate to effect a colloidal dispersion of insoluble Luminide. These preparations are administered as injectables including intramuscular and intravenous administration.

Topical Luminides can be prepared as a cream, lotion, gel, and ointment.

It is also possible to administer the active compounds as such without excipients or diluents, in a suitable form, for example in capsules.

Luminides can be packaged employing the usual sorts of precautious which the pharmacist generally observes. For example, the preparations may be packaged in light protecting vials and may be refrigerated if necessary.

EXEMPLARY LUMINIDE PHARMACEUTICALS

Prostaglandins possess potent renal, cardiac, hemodynamic, and other physiological effects; however, the free agents are 95% inactivated during one passage through the pulmonary circulation and are essentially eliminated in 90 seconds from intravascular injection. A luminide which is resistant to intravascular inactivation comprising a C functionality of prostaglandin A_1 A_2, B_1, E_1, E_2, or an analogue which possesses a vasodilatory effect on coronary arteries and other human vascular beds is an agent for the treatment of ischemic heart disease and is a antihypertensive agent with a long halflife. A luminide which is resistant to intravascular inactivation comprising a C functionality of postaglandin E, F, A or an analogue which possesses a positive cardiac inotropic effect is an inotropic agent with a long halflife. A luminide which is resistant to intravascular inactivation comprising a C functionality of prostaglandin A, E, or an analogue prostaglandin which possesses natriuretic and diuretic activity is a diuretic agent with a long halflife. A luminide which is resistant to intravascular inactivation comprising a C functionality of prostaglandin A, G, E_1, E_2 or an analogue such as 15(S)-15-methyl PGE_2 methylester, 16,16-dimethyl PGE_2, AY-22,093, AY-22,469, AY-22,443, or 15(R)-15-methyl PGE_2 which inhibits

gastric acid secretion is an agent for the treatment of peptic and duodenal ulcer disease with a long halflife. A luminide which is resistant to intravascular inactivation comprising a C functionality of prostaglandin D_2, E_1 or an analogue which inhibits platelet aggregation is an antithromboembolic agent with a long halflife. A luminide which is resistant to intravascular inactivation comprising a C functionality of prostaglandin E_1, E_2 or an analogue which causes bronchial dilatation is an agent for the treatment of asthma and allergic and hypersentivity reactions with a long halflife. A luminide which is resistant to intravascular inactivation comprising a C functionality of prostaglandin F_2 or an analogue which causes abortion by luteolysis is an agent for therapeutic abortion with a long halflife. A luminide which is resistant to intravascular inactivation comprising a C functionality of prostaglandin A_2, E_1, E_2, or an analogue which induces erythropoiesis by stimulating the release of erythropoietin from the renal cortex is an agent for the treatment of anemia. A luminide which is resistant to intravascular inactivation comprising a C functionality of prostaglandin E or an analogue which modulates T lymphocytes to decrease their ability to reject an allogenic graft is an agent to prolong allograft survival.

A cellular permeant luminide comprising a C functionality of cellular impermeant 2' -isopropyl -4' -(trimethylammonium chloride) -5' -methylphenyl piperidine -1-carboxylate (Amo 1618) which inhibits the cyclization of trans-geranyl-geranyl-PP to copalyl-PP during Kaurene synthesis is a fungicidal agent.

A cellular permeant luminide comprising a C functionality of cellular impermeant adenosine cyclic 3', 5'-monophosphate or an analogue which inhibits the release and formation of phlogistic mediators such as histamine and kinins is an agent for treating asthma and hypersensitivity and anaphylactic reactions.

A cellular permeant luminide comprising a C functionality of cellular impermeant 4'-sulfamylphenyl – 2-azo –7-acetamido –1-hydroxynaphthalene –3,6-disulfonate (Neoprontosil), 4'-sulfamyl –2, 4-diaminoazobenzene (Prontosil), or 5-(p-sulfamylphenylazo) salicylic acid (Lutazol) which possess potent carbonic acid anhydrase inhibition is a diuretic agent.

A cellular permeant luminide comprising a C functionality of a cellular impermeant analogue of S-adenosyl homocysteine or sinefungin is an oncostatic agent.

A cellular permeant luminide comprising a C functionality of the cellular impermeant phosphoglycolohydroxamate which inhibits Class II aldolases present in bacterial and fungi and is noninhibitory of Class I aldolases present in animals is an antibacterial and antifungal agent.

A cellular permeant luminide comprising a C functionality of a cellular impermeant inosine analogue such as formycin B which inhibits nucleotide phosphorylase during nucleotide metabolism is an agent for disorders of purine metabolism such as gout, is an agent that alters the toxicity and/or antitumor behavior of other analogue – containing nucleosides such as 6-thioguanosine or 6-mercaptopurine ribonueleoside, and is an immunosuppressive agent by disruption of purine metabolism.

A cellular permeant luminide comprising a C
functionality of cellular impermeant phosphonoformate
(Foscarnet) which inhibits the HIV reverse
transcriptase enzyme is an agent for the treatment of
acquired immunodeficiency syndrome. The synthesis and
the results of treatment of C3H mice infected with
Raucher Spleen Focus Forming Virus with MTL J-1, a
cellular permeant luminide comprising a C
functionality of phosphonoformate, is given in
Experimental Secions 1 and 3, respectively.

A cellular and blood-brain barrier permeant
luminide comprising a C functionality of cellular and
blood brain-barrier impermeant γ-amino-butyric acid
(GABA) which is the major inhibitory neurotransmitter
in the mannalian central nervous system or comprising
a C functionality of a cellular and blood-brain
barrier impermeant inhibitor of the GABA-degrading
enzyme, GABA: 2-oxoglutarate aminotransferase such as
gabaculine, N-(5'-phosphopyridoxyl) -4-aminobutyric
acid, ethanolamine -o-sulfate, γ-vinyl GABA, or
γ-acetylenic GABA; or comprising a C functionality of
a cellular and blood-brain barrier impermeant compound
which enhances GABA release such as Baclofen is an
anti-convulsant, muscle relaxant, sedative, and
anxiolytic agent.

A cellular permeant luminide comprising a C
functionality of a cellular impermeant oligonucleotide
which binds to RNA or DNA and blocks transcription or
translation of HIV or P-glycoprotein gene products is
an agent for the treatment of AIDs and
chemotherapeutic drug, resistance, respectively.

A blood-brain barrier permeant luminide
comprising a C functionality of blood-brain barrier
impermeant adenosine which binds to brain purinergic

- 180 -

receptors to suppress opiate withdrawal is an agent for the management of opiate withdrawal syndrome.

A slowly releasing peripherally acting luminide comprising a C functionality of adenosine which causes coronary vasodilatation is a long acting agent for the treatment of ischemic heart disease.

A cellular permeant luminide comprising a C functionality of cellular impermeant 3-hydroxy -3-methylglutarate, 3-hydroxybutyrate, 3-hydroxy -3-methylpentanoate, 4-bromocrotonyl -CoA, but-3-ynoyl -CoA, pent -3-ynoyl -CoA, dec -3-ynoyl-CoA, ML-236A, ML-236B (compactin), ML-236C, mevinolin, mevinolinic acid, or a mevalonic acid analogue which is an inhibitor of 3-hydroxy -3-methylglutaryl -CoA reductase which catalyzes the rate-limiting and irreversible step of cholesterol synthesis where inhibition at this step does not lead to the accumulation of nonmetabolizable precursors is an anticholesterol agent.

A cellular permeant luminide comprising a C functionality of cellular impermeant thioinosinate which suppresses T lymphocytes is an immunosuppressant agent.

A cellular permeant luminde comprising a C functionality of cellular impermeant Suramin, which is a powerful inhibitor of energy driven calcium uptake by the sarcoplasmic reticulum and is an intracellular inhibitor of Na^+-K^+ ATPase where both activities increase intracellular calcium concentrations with a concomitant inotropic effect is a cardiac inotropic agent.

A cellular permeant luminide comprising a C functionality of a cellular impermeant norepinephrine N-methyltransferase inhibitor such as 2,3-dichloro -α-methylbenzylamine, 2,3-dichlorobenzylamine,

- 181 -

2,3-dichlorobenzamidine,   or   3,4-dichlorophenyl-
acetamidine is a specific epinephrine action blocking
agent.

A cellular permeant luminide comprising a C
functionality of cellular impermeant adenosine cyclic
3',5'-monophosphate or a cAMP analogue which blocks
the synthesis of fatty acids and cholesterol in the
liver is an antilipidemic agent.

A cellular permeant luminide comprising a C
functionality of a cellular impermeant inhibitor of
dihydroxyphenylalanine decarboxylase during the
synthesis of epinephrine and norepinephrine such as
psitectorigenin, genistein, 3',4',5,7-tetrahydroxy-
8-methylisoflavone, orbol, 8-hydroxygenistein,
3',5,7-trihydroxy-4',6-dimethylisoflavone, 3',5,7-tri-
hydroxy-4',8-dimethoxyisoflavone, D,L-B-(5-hydroxy-3-
indolyl)-α-hydrazinopropionic acid, D,L-α-hydra-
zino-α-methyldopa, D,L-B-(3-indolyl) -α-hydrazino-
propionic acid, a derivative of phenylalanine such as
N-methyl-3,4-dopa, α-acetamido-3,4-dimethyoxy-
cinnamic acid, DL-α-methyl-3,4-dopa, α-methyl-
B-(3-hydroxy-4- methoxyphenyl)alanine, α-methyl-
3,4-dimethoxyphenylalanine, or d-catechin; D,L-B-(3-
indolyl)-α-methyl-α- hydrazinopropionic acid
(R)-3[3,4-dihydroxyphenyl]-1- fluoropropylamine,
(S)-α-fluoromethyldopa, (S)-α-fluoromethyl-
tyrosine, 5-(3,4-dihydroxycinnamoyl) salicylic acid,
3-hydroxycinnamic acid, caffeic acid, 3-mercapto-
cinnamic acid, α-methyl-3-hydroxycinnamic acid,
α-ethyl-3- hydroxycinnamic acid, 3-hydroxy-w-
nitrostyrene, 3,4-dihydroxyhydrocinnamic acid,
3-hydroxybenzalacetone, 3-hydroxychalone, 3-hydroxy-
benzal furanyl ketone, 3-hydroxybenzal thiophenyl
ketone, 3',4'-dihydroxyflavone, 8-0-glucoseflavone,
flavone, 3-hydroxyphenyl pyruvic acid, 3,4-dihydroxy-

- 182 -

phenylpyruvic acid phenylthiopyruvic acid, 4-hydroxy-
phenylpyruvic acid, dithiosalicyclic acid, 1-hydroxy2-
naphthoic acid, 3-hydroxy-7-sulfo-2-naphtholic acid,
3,5-dihydroxy-2-naphtholic acid, 4-chlorocinnamic
acid, 2-chlorocinnamic acid, 2,4-dichlorocinnamic
acid, 3-nitrocinnamic acid, 3,5-dibromo-2-hydroxycin-
namic acid, 2,4,6-triiodo -3-hydroxycinnamic acid,
2-hydroxy-4'-cyanochalone, 4-(4-hydroxycinnamoyl)
benzylnitrile, 2-(4-hydroxycinnamoyl) -1,4-dihydroxy-
benzene, quercetin-6'-sulfonic acid, 5-(2-hydroxy-3,5-
dibromocinnamoyl) salicylic acid or 5-(3-hydroxycin-
namoyl) salicylic acid is an antihypertensive agent.

     A sperm permeant luminide comprising a C
functionality of sperm impermeant inhibitors of
acrosin, a proteolytic enzyme located in the acrosome
of sperm, such as tosyl lysine chloromethyl ketone,
N-α-tosyl-L-arginine chloromethyl ketone, or ethyl
p-guanidinobenzoate is a contraceptive agent.

     A cellular permeant luminide comprising a C
functionality of cellular impermeant adenosine cyclic
3',5'-monophosphate (cAMP), N^6 ,O^2-dibutyry-
ladenosine cyclic 3',5'-monophosphate or an analogue
which produces an inotropic response is a cardiac
inotropic agent.

     A cellular permeant luminide comprising a C
functionality of a cellular impermeant adenosine
kinase enzyme inhibitor such as 6,6'-dithiobis
(9-B-D-ribofuranosylpurine) is a chemotherapeutic
agent and an immunosuppressive agent.

     A mitochondrial and blood-brain barrier permeant
luminide comprising a C functionality of a mito-
chondrial and blood-brain barrier impermeant inhibitor
of monoamine oxidase such as phenylhydrazine, phenyl-
ethylidenehydrazine, isopropylhydrazine, or iproniazid
is an antidepressant.

- 183 -

A cellular and blood-brain barrier permeant luminide comprising a C functionality of a cellular and blood-brain barrier impermeant inhibitor of catechol-o-methyltrasferase such as 3,5-diiodo-4-hydroxybenzoic acid, S-3'-deoxyadenosylL-homocysteine, pyrogallol, RO4-4602, gallic acid, 3,5-dihydroxy-4-methylbenzoic acid, 1,3-dihydroxy-2-methoxybenzene, 1-hydroxy-2,3-dimethoxybenzene, 2-hydroxy-1,3-dimethoxybenzene, 1,3-dihydroxy-4-methoxybenzene, catechol, 3,4-dihydroxybenzoic acid, caffeic acid, 5,6-dihydroxyindole, noradnamine, dopacetamide, H 22/54, quercetin, nordihydroguaiaretic acid, U-0521, arterenone, methylspinazarin, MK 486, dopa, papaveroline, isoprenaline, 7,8-dihydroxy-chlorpromazine, 3-hydroxy-4-pyridone, tetrahydroi-soquinoline pyridoxal 5'-phosphate, iodoacetic acid, 3-mercaptotyramine, dehydrodicaffeic acid dilactone, methylspinazorin, 3',5,7-trihydroxy-4',6-dimeth-oxyisoflavone, 3',5,7-trihydroxy- 4',8-dimeth-oxyisoflavone, 6,7-dihydromethylspinazarin, S-adenosylhomocysteine, S-tubercidinylhomocysteine, 3',8-dihydroxy-4',6,7-trimethoxyisoflavone,7-0-methylspi nochrome B, 6-(3-hydroxybutyl)-7-0-methylspinachrome B, 3,5-diiodosalicyclic acid, or pyridoxal-5'-phosphate is an antidepressant agent which increases brain levels of monoamines and is an agent to block the metabolism of L-dopa administered for the treatment of Parkinsonism.

A cellular permeant luminide comprising a C functionality of a cellular impermeant inhibitor of adenosine deaminase which blocks the metabolism of adenosine such as coformycin, arabinosyl-6-thiopurine, 6-methylthioinosine, 6-thioinosine, 6-thioguanosine, N^1-methyladenosine, N^6-methyladenosine, 2-fluorodeoxyadenosine, 2-fluoroadenosine, inosine,

- 184 -

2'-deoxyinosine, deoxycoformycin, 1,6-dihydro-6-hydroxymethyl purine ribonucleoside, erythro-9-(2-hydroxy-3-nonyl)adenine, or 9-B-D-arabinofuranosyl-6-hydroxylaminopurine is a vasodilatory agent, an immunosuppressive agent, a chemotherapeutic potentiating agent, and an agent to enhance cardiac recovery following ischemia. The mechanism in the first case involves the accumulation of adenosine which is a vasodilatory agent; the mechanism in the second case involves disruption of purine metabolism; the mechanism in the third case involves the disruption of the degradation of purine analogue chemotherapeutic agents; the mechanism in the fourth case involves blocking the loss of catabolic products of adenosine triphosphate in the form of purine nucleotides and oxypurines during ischemia. Additional luminides effective in enhancing post ischemic cardiac recovery by the latter mechanism include those with C moietics of inhibitors of adenylate kinase, 5'-nucleotidase, and adenosine translocase such as p^1,p^5-diadenosine pentaphosphate, α,B-methylene adenosine diphosphate, and nitrobenzyl-6-thioinosine, respectively.

A blood-brain barrier permeant luminide comprising a C functionality of a blood-brain barrier impermeant inhibitor of γ-aminobutyric acid uptake such as D,L-2,4-diaminobutyric acid, D,L-B-hydroxy GABA, (-)-nipecotic acid, trans-4-aminocrotonic acid, cis-3-aminocyclopentane- 1-carboxylic acid, trans-3-aminocyclopentane-1-carboxylic acid, B-guanidino-propionic acid, homohypotaurine, 4-aminopentanoic acid, homotaurine, B-alanine, imidazoleacetic acid, 6-aminohexanoic acid, D,L-carnitine, D,L-2,6-diamino-pimelic acid, D,L-2-fluoro GABA, guanidino acetic acid, 2-hydrazinopropionic acid, taurine, D,L-orni-

thine, or sulphanilamine potentiates the inhibitory
action of GABA and is a muscle relaxant, anticon-
vulsant, sedative, and anxiolytic agent.

A cellular permeant luminide comprising a C
functionality of cellular impermeant inositol
1,4,5-triphosphate which is a major second messenger
for stimulating a whole range of cellular processes
such as contraction, secretion, and metabolism is an
agent for activating these processes including
secretion of neural transmitters to function as an
agent for the treatment of mental disorders or
secretion of insulin to function as a hypoglycemic
agent.

A cellular permeant luminide comprising a C
functionality of cellular impermeant guanosine 5'
cyclic monophosphate or 8-bromo guanosine 5' cyclic
monophosphate which relaxes smooth muscle is an
antihypertensive and bronchodilator agent.

A cellular and blood-brain barrier permeant
luminide comprising a C functionality of a cellular
and blood-brain barrier impermeant inhibitor of the
uptake system for glycine, the inhibitory synaptic
transmitter of the spinal cord, such as
hydrazinoacetic acid is an agent for spinal reflex
inhibition.

A cellular permeant luminide comprising a C
functionality of a cellular impermeant isoquinoline-
sulfonamide inhibitor of protein kinase C,
cAMP-dependant protein kinase, or cGMP-dependent
protein kinase such as N-(2-aminoethyl)- 5-isoquino-
linesulfonamide is an agent which blocks the
secretion, contraction, and metabolic events regulated
by these mediators of external physiologic stimuli.

A cellular permeant luminide comprising a C
functionality of cellular impermeant Ribavirin which

- 186 -

is active against HSV-1 and 2, hepatitis, and
influenza viruses, or phosphonoacetic acid which is a
highly specific inhibitor of Herpes Simplex virus
induced polymerase and is active against HSV-1 and
HSV-2, or adenine arabinoside (ara-A), cytosine
arabinoside (Ara-C), ara-A 5'-monophosphate (ara-AMP),
or hypoxanthine arabinoside (ara-Hx) which is active
against HSV or phagicin which is active against
vaccinia and HSV, or 4-fluoroimidazole, 4-fluoroimi-
dazole-5-carboxylic acid, 4-fluoroimidazole- 5-carbox-
amide,   5-fluoro-1-B-D-ribofurano-   sylimidazole-4-
carboxamide, 5-amino-1-B-D-ribofuranosyl- imidazole-4-
carboxamide,   poly (I) • poly (C),   sinefungin,
iododeoxyuridine,   9-(2-hydroxy-ethoxymethyl) guanine,
gliotoxin,   distamycin   A,   netropsin,   congocidine,
cordycepin,   1-B-D-arabinofuranosylthymine,   5,6-di-
hydroxy-5-azathymidine, pyrazofurin, toyocamycin, or
tunicamycin is an antiviral agent.

A cellular permeant luminde which comprises a C
functionality of a cellular impermeant inhibitor of
fungal chitin synthetase such as polyoxin D, nikko-
mycin Z, or nikkomycin X; or which comprises a C
functionality of an impermeant antifungal agent such
as   ezomycin A_1, A_2, B_1, B_2, C_1, C_2, D_1,
or D_2 or platenocidin, septacidin, sinefungin,
A9145A, A9145C, or thraustomycin is an antifungal
agent.

A   blood-brain   barrier   permeant   luminide
comprising a c functionality of a blood-brain barrier
impermeant inhibitor of central nervous system
carbonic   anhydrase   such   as   methazolamide,   or
2-benzoylimino-3-methyl-Δ^4-1,3,4-thiadiazoline-
5-sulfonamide substituted at the benzolyl group with
3,4,5-trimethoxy, 2,4,6-trimethoxy, 2,4,5-trimethoxy,

4-chloro, 4-bromo, 4-iodo, or hydrogen is an anticonvulsant agent.

A cellular and blood-brain barrier permeant luminide comprising a C functionality of a cellular and blood-brain barrier impermeant inhibitor of dopamine-B-hydroxylase during the synthesis of norepinephrine and epinephrine such as fuscaric acid, 5-(3',4'-dibromobutyl)picolinic acid, 5-(3'-bromo-butyl) picolinic acid, 5-(3',4'-dichlorobutylpicolinic acid, YP-279, benzyloxyamine, p-hydroxybenzyloxyamine, U-21,179, U-7231, U-6324, U-0228, U-5227, U-10,631, U-10,157, U-1238, U-19,963, U-19,461, U-6628, U-20,757, U-19,440, U-15,957, U-7130, U-14,624, U-22,996, U-15,030, U-19,571, U-18,305, U-17,086, U-7726, dimethyldithiocarbamate, diethyldithio-carbamate, ethyldithiocarbamate, 2-mercaptoethyl-guanidine, thiophenol, 2-mercaptoethylamine, 3-mercap-topropylguanidine, 3-mercap- topropyl-N-methyl-guanidine, 2-mercaptoethanol, 2-mercaptoethyl-N-methylguanidine, 2-mercaptoethyl-N,N'- dimethyl-guanidine, 4,4,6-trimethyl -3,4-dihydropyrimidine-2-thiol, N-phenyl-N'-3-(4H-1,2,4-trizolyl)thiourea, methylspinazarin, 6,7-dimethylspinazarin, 7-0-methy-spinochrome B, 6-(3-hydroxybutyl)-7-0-methylspina-chrome B, aquayamycin, chrothiomycin, frenoclicin, N-n-butyl-N'-3-(4H-1,2,4-trazolyl) thiourea, propyl-thiouracil, mimosine, mimosinamine, or mimosinic acid is an antihypertensive agent.

A cellular permeant luminide of a cellular impermeant inhibitor of histidine decarboxylation during the synthesis of histamine such as 2-hydroxy-5-carbomethoxybenzyloxyamine, 4-toluene-sulfonic acid hydrazide, 3-hydroxy benzyloxyamine, hydroxylamine, aminooxyacetic acid, 4-bromo-3-hydroxy-benzyloxyamine (NSD-1055), rhodanine substituted in

the 3 position with p-chlorophenethyl, p-chlorobenzyl,
p-methylthiobenzyl,   p-methylbenzyl,   p-fluorobenzyl,
amino, 3,4-dichlorobenzyl, p-bromobenzyl, p-methoxy-
benzyl,   p-bromoanilino,   p-iodoanilino,   p-chloro-
anilino, p-toluidino, anilino, 2,5-dichloroanilino,
dimethylamino,   or   p-methoxyphenyl;
2-mercaptobenzimidazole-1,3-dimethylol,   4-bromo-3-
hydroxy   -benzoic   acid,   4-bromo-3-hydroxybenzyl
alcohol,   4-bromo-3-hydroxy-hippuric   acid,   (R,S)-α-
fluoromethyl-   histidine,   (S)-α-fluoromethylester,
L-histidine ethyl ester, L-histidinamide, D,L-3-amino-
4-(4-imidazolyl)-2-butanone,   2-bromo-3-hydroxy-
benzyloxyamine,   5-bromo-3-   hydroxybenzyloxyamine,
4,6-dibromo-   3-hydroxybenzyloxyamine,
aminooxypropionic   acid,   benzyloxyamine,   4-bromo-3-
benzenesulfonyloxybenzyloxyamine,   3',5,7-trihydroxy-
4',6-   dimethoxyisoflavone,   lecanoric   acid,
N-(2,4-dihydroxybenzoyl)- 4-aminosalicylic acid, or
3',5,7-trihydroxy-4',8-   dimethoxyisoflavone   is   an
agent for the treatment of allergy, hypersensitivity,
gastic ulcer, and inflamation.

Luminides   also   comprise   C   functionalities   of
pharmaceutical molecules as appear in Physicians Desk
Reference, Edward R. Barnhart, 41th ed., 1987, Medical
Economics Company Inc., N.J.; USAN and the Dictionary
of Drug Names, ed. by Mary C. Griffiths, The United
States Pharmacopedial Convention, (1986); and The
Pharmacological Basis of Therapeutics, ed. by A.G.
Gilman, L. Goodman, A. Gilman, 7th ed., (1985),
MacMillan Publishing Co., N.Y., N.Y., (incorporated by
reference) where the pharmacokinetics and/or the
pharmacodynamics of these agents are altered via
delivery to the site of action by way of a luminide
agent such that the therapeutic effect or therapeutic

ratio is enhanced.   Some examples follow which are not
meant to be exhaustive.

A luminide with high permeance to the blood-brain
barrier comprising a C functionality of a centrally
acting converting enzyme inhibitor such as captopril
which possesses a lesser blood-barrier permeance is an
agent with increased efficacy of the central nervous
system antihypertensive effect of the centrally acting
converting enzyme inhibition including captopril.

A luminide with an A moiety which reacts with
free radicals and electron carriers in the cytosol of
bacteria to effect release of the C moiety and which
possesses greater permeance or B-lactamase resistance
than its C moiety of a bacterial wall synthesis
inhibitor such as a penicillin, cephalosporin, or
cephamycin is a more efficacious and broad spectrum
antibacterial agent than the free C moiety.

A   luminide   possessing   more   favorable
pharmacokinetics or pharmacodynamics than its C moiety
of an agent which blocks bacterial synthesis of
tetrahydrofolate such as a sulfonamide (an analogue of
p-aminobenzoic   acid)   including   sulfanilamide,
sulfadiazine,   sulfamethoxazole,   sulfisoxazole,   or
sulfacetamide   or   an   inhibitor   of   dihydrofolate
reductace   including   pyrimethamine,   cycloguanil,
trimethoprin, isoaminopterin, 9-oxofolic acid, or
isofolic acid is a more efficacious antibacterial than
the free C moiety.

A luminide possessing more favorable pharmaco-
kinetics or pharmacodynamics than it C functionality
of a bactericidal agent such as nalidixic acid or
oxolinic acid is a more efficacious antibacterial than
the free C moiety.

A luminide possessing more favorable pharmaco-
kinetics or pharmacodynamics than its C moiety of an

inhibitor of bacterial protein synthesis such as
vancomycin, an aminogylcoside, erythromycin,
tetracyclin, or chloramphenicol is a more efficacious
antibacterial agent than the free C moiety.

A luminide prossessing more favorable pharmaco-
kinetics or pharmacodynamics than its C moiety of an
inhibitor of viral DNA polymerase such as vidarabine
is a more efficacious antiviral agent than the free
C moiety.

A luminide possessing more favorable pharmaco-
kinetics or pharmacodynamics than its C moiety which
is tuberculostatic or tuberculocidal such as isoniazid
or aminosalicyclic acid is a more efficacious agent
for the treatment of tuberculosis than the free
C moiety.

A luminide possessing more favorable pharmaco-
kinetics or pharmodynamics than its C moiety of an
anthelmintic agent such as oxamniquine, piperazine,
metronidazole, diethylcarbamazine, paromomycin,
niclosamide, bithionol, metrifonate, hycanthone,
dichlorophen, or niclosamide is a more efficacious
anthelmintic agent than the free C moiety.

A luminide possessing more favorable pharmaco-
kinetics or pharmacodynamics than its C moiety of an
H_2-blocking agent such as cimetidine or ranitidine
is a more efficacious anti-ulser agent than the free
C moiety.

A luminide possessing more favorable pharmaco-
kinetics or pharmacodynamics than its C moiety of an
agent which blocks release of norepinephrine such as
sotalol, guanethidine, pindolol, pronethalol, KO 592,
practolol, oxprenolol, or pronethalol is an
antiarrhythmic, antihypertensive and antipsychotic
agent.

A luminide possessing more favorable pharmaco-
kinetics or pharmacodynamics than its C moiety of a
xanthine oxidase inhibitor such as allopurinol,
thioinosinate, 5,7-dihydroxypyrazolo [1,5-a]
pyrimidine substituted at the 3 position with
hydrogen, nitro, bromo, chloro, phenyl, 3-pyridyl,
p-bromophenyl, p-chlorophenyl, p-acetylanilino,
p-tolulyl, m-tolulyl, naphthyl, or 3,4-methyl-
enedioxyphenyl; 8-(m-bromoacetamidobenzyl-
thio)hypoxanthine, 8-(m-bromoacetamidobenzyl-
thio)hypoxanthine, guanine substituted at the 9
position with phenyl, 4-chlorophenyl, 3-chlorophenyl,
3,4-dichlorophenyl, 4-methoxyphenyl, 3,4-dimeth-
oxyphenyl, 4-dimethylaminophenyl, 4-aminophenyl,
3-aminophenyl, 3-trifluormethylphenyl, 4-benzamido,
4-carboxylphenyl, 4-methylpheyl, 4-ethylphenyl,
3-methylphenyl, B-naphthyl, or 4-ethoxyphenyl;
4,6-dihydroxypyrazolo [3,4-d] pyrimidine, 4-trifluoro-
methylimidazoles substituted at the 2 position with
phenyl, p-chlorophenyl, p-methoxyphenyl, p-acetylani-
lino, p-nitrophenyl, p-dimethylaminophenyl, p-cyano-
phenyl, p-fluorophenyl, p-carboxyphenyl, m-chloro-
phenyl, 3,4-dichlorophenyl, 4-pyridyl, 3-pyridyl,
2-quinolyl, 6-quinolyl, 4-quinolyl, 7-quinolyl,
2-pyrazinyl, or 1-(2-pyridyl-4-trifluoromethyl-
5-bromoimidazolyl; 5-(4-pyridyl)-1,2,4-triazoles
substituted at the 5 position with 4-pyridyl,
3-pyridyl, 2-pyridyl, phenyl, p-chlorophenyl,
m-chlorophenyl, p-sulfonamidophenyl, 3,5-dichloro-
phenyl, 3,5-dicarboxyphenyl, 6-quinolyl, 2-furyl,
4-pyridazinyl, 2-thienyl, 2-pyrimidinyl, 4-pyrimi-
dinyl, or 4-pyrazinyl; difunisal, 4(or 5)-(2-amino-
ethylthio-azo)imidazole-5(or 4)-carboxamide, 4 (or
5)-diazoimidazole-5(or 4)-carboxamide , or S-[5(or
4)-carbamoyl-4(or 5)-imidazolyl azo] cysteine is a

more efficacious agent for the treatment of gout and hyperuricemic conditions than the free C moiety.

A luminide possessing more favorable pharmaco-kinetics or pharmacodynamics than its C moiety which inhibits DNA synthesis such as a bis-thiosemicar-bazone, 3,5-diisopropylsalicyl- hydroxamic acid, 4-hydroxybenzoylhydroxamic acid, 3-methylsalicyl-hydroxamic acid 2,5-dihydroxybenzoylhydroxamic acid, or 2-hydroxy-3,4,5-trimethoxybenzoylhydroxamic acid; or which inhibits nucleotide synthesis such as N-(phosphoacetyl)-L-aspartate which inhibits asparatate transcarbamylase during pyrimidine synthesis, or azaserine or 6-diazo-5-oxo-L-norleucine which inhibits purine synthesis at the phosphori-bosyl-formyl-glycineamidine synthetase step; or which is an antifolate such as methotrexate, 2,4-diamino-5-benxyl-6-(4-phenylbutyl) pyrimidine, 2,4-diamino- 5-phenyl-6-(4-phenylbutyl) pyrimidine, 2,4-diamino-5-phenyl- 6-(3-anilinopropyl) pyrimidine, 2-amino-4-hydroxy-5-phenyl- 6-(3-p-aminobenzoyl-glutamic acid propyl) pyrimidine, N-[p-[[(2,4-diamino-6-quinazolinyl)methyl]methylamino] benzoyl]-L-glutamic acid, N-[p-[2,4-diamino-5-methylquinazolinyl)methylamino]benzoyl] -L-aspartic acid, N-[p-[[(2-amino-4-hydroxy-6-quinazolinyl) methyl]methylamino] benzoyl]-L-glutamic acid, 2,4-diaminoquinazolines: CCNSC 105952, CCNSC 112846, CCNSC 121346, CCNSC 122761, CCNSC 122870, CCNSC 529859, CCNSC 529860, or CCNSC 529861; 8-aza GMP, 7-deaza-8-aza GMP, 2'-dGMP, B-D-arabinosyl GMP, pentopyranine A-G, B-ribofuranosyl-1,3-oxazine-2,4-dione, pyrazofurin, 6-(p-chloroacetylanilinomethyl)-5-(p-chlorophenyl)-2,4- diaminiopyridine, 6-(p-chlora-cetylvinylanilinomethyl)-5- (p-chlorophenyl)-2,4-diaminopyridine, 6-(p-chloroacetyl- ethylanilino-

- 193 -

methyl)-5-(p-chlorophenyl)-2,4-diamino   pyridine,
6-(p-chlorophenylbutylanilinomethyl)-5-(p-chlorophenyl)-
2,4- diamino pyridine, p-(2,6-diamino-1,2-dihydro-2,
2-dimethyl-   S-triazin-1-yl)   phenylpropionyl
sulfanilylfluoride or variants of the propionamide
bridge   of   acrylamido,   N-ethylsulfonamido,
N-ethylcaboxamido, oxyacetamido, or oxythyloxy; or
which inhibits purine or pyrimidine synthesis such as
xylosyladenine,   6-azauridine,   5-aminouridine,
5-azaorotic   acid;   or   which   inhibits   nucleotide
interconversion   such   as   hadacidin,   6-mercaptopurine,
azathioprine,   nitro-dUMP,psicofuranine,   decoyinine,
5-fluorouracil,   5-fluorodeoxyuridine,   shadowmycin;   or
which inhibits nucleotide utilization such as cytosine
arabinoside,   arabinosyladenine;   or   which   becomes
incorporated   into   polynucleotides   such   as   8-azagua-
nine,   tubercidine,   toyocamycin,   sangivamycin,
formycin,   7-deazainosine,   8-azainosine,   or   7-thia-7,
9-dideazainosine; or which is a glyoxalase inhibitor
such as Glyo-I, or Glyo-II, is a more efficacious
antineoplastic agent than the free C moiety.

A luminide possessing more favorable pharmaco-
kinetics or pharmacodynamics than its C moiety of an
agent which blocks synthesis of prostaglandin A_2
which effects platelett aggregation such as salicylic
acid,   pyrogallol,   5,8,11,14-eicosatetraynoic   acid,
α-naphthol,   guaiacol,   propylgallate,   nordihydro-
guiaretic acid, N-0164, benzydamine, 9,11-azoprosta-5,
13-dienoic acid, 2-isopropyl-3-nicotinylindole, is a
more efficacious antithrombotic agent than the free
C moiety.

A luminide possessing more favorable pharmaco-
kinetics or pharmacodynamics than its C moiety of an
agent which blocks prostaglandin synthetase such as
indomethacin,   sulindac,   tolmetin,   mefenamic   acid,

- 194 -

ibuprofen, naproxen, fenoprofen, fluribiprofen, ketoprofen, meclofenamic acid, flufenamic acid, niflumic acid, benzydamine, oxyphenbutazone, asprin, acetaminophen, salicylamide, 0-carboxydiphenylamine, tolectin, diclofenac, 2,7-dihydroxynaphthalene, 5-(4-chlorobenzoyl)- 1-methylpyrrole-2-acetic acid, 5-(4-methylbenzoyl)-1,4- dimethylpyrrole-2-acetic acid, 5-(4-chlorobenzoyl)-1,4- dimethylpyrrole-2-acetic acid, 5-(4-fluorobenzoyl)-1,4- dimethylpyrrole-2-acetic acid, 5-(4-chlorobenzoyl)-1,4-dimethylpyrrole-2-(2-propionic acid), 5,6-dehydro-arachidonate, 11,12-dehydroarachidonate, or 5,8,11,14-eicosatetraynoate; or of an agent which blocks lipoxygenase or blocks leukotriene action such as BW755C, FPL 55712, or U-60,257 is a more efficacious nonsteroidal anti-inflammatory agent than the free C moiety.

A luminide possessing more favorable pharmaco-kinetics or pharmacodynamics than its C moiety of an antiarrhythmic agent such as procainamide or quinidine is a more efficacious antiarrhythmic agent than the free C moiety.

A luminide possessing more favorable pharmaco-kinetics or pharmacodynamics than its C moiety of an inhibitor of hepatic synthesis of Vitamin K dependent clotting factors such as warfarin sodium, dicumarol, 4-hydroxycoumarin, phenprocoumon, or acenocoumarol is a more efficacious anticoagulant than the free C moiety.

A luminide possessing more favorable pharmaco-kinetics or pharmacodynamics than its C moiety which directly relaxes vascular smooth muscle such as hydralazine, minoxidil, or isoxsuprine is a more efficacious antihypertensive agent than the free C moiety.

A luminide possessing more favorable pharmaco-
kinetics or pharmacodynamics than its C moiety of a
Na^+-K^+-ATPase inhibitor such as digtoxigenin,
digoxigenin, cymarol, periplogenin, or strophan-
thidiol, or ouabain glycosides, cardenolides, or basic
esters, or   ICI-63,632,   ICI-63,605,   ICI-62-655,
ICI-62,838,   ICI-69,654,   ICI-58,622,   ICI-61,374,
ICI-57,267,   ICI-61,424,   ICI-61,411,   ICI-65,199,
ICI-70,898,   ICI-70,899,   ICI-70,900,   ICI-70,901,
ICI-62,966,   ICI-65,210,   ICI-63,116,   ICI-62,936,
ICI-65,551,   ICI-63,978,   ICI-62,276,   ICI-63,056,
ICI-67,135,   ICI-67,167,   ICI-67,134,   ICI-67,875,
ICI-67,880, or ICI-61,558 is a more efficacious
inotropic agent than the free C moiety.

A luminide possessing more favorable pharmaco-
kinetics or pharmacodynamics than its C moiety which
is a calcium channel blocker such as prenylamine,
verapamil, fendiline, gallopamil, cinnarizine,
tiapamil, diltiazem, bencyclan, or nifedipine; or an
agent which stabalizes calcium binding to cellular
calcium stores and thereby inhibits the release of
this calcium by contractile stimuli such as
8-(N,N-diethylamino)-octyl   3,4,5-trimethoxybenzoate
(TMB-8) is a more efficacious vasodilatory agent than
its free moiety.

A luminide possessing more favorable pharmaco-
kinetics or pharmacodynamics than its C moiety of a
monoamine oxidase inhibitor such as tranylcypromine,
phenylethylamine, trans-cinnamic acid, phenelzine, or
isocarboxazid is a more efficacious antidepressant
agent than the free C moiety.

A luminide possessing more favorable pharmaco-
kinetics or pharmacodynamics than its C moiety of a
benzodiazepine compound such as clorazepate is a more
efficacious tranquillizer than the free C moiety.

A luminide possessing more favorable pharmaco-
kinetics or pharmacodynamics than its C moiety of an
antiseizure agent such as valproic acid is a more
efficacious antiepileptic agent than the free C moiety.

A luminide possessing more favorable pharmaco-
kinetics or pharmacodynamics than its C moiety of an
agent which causes repression of the synthesis of
HMG-CoA reductase such as 20-α-hydroxycholesterol,
22-ketocholesterol,   22-α-hydroxycholesterol,
25-hydroxycholesterol,   22-B-hydroxycholesterol,
7-α-hydroxycholesterol,   7-B-hydroxycholesterol,
7-ketocholesterol, or kryptogenin; or of an agent
which inhibits HMG-CoA reductase such as, lorelco; or
of an agent which inhibits lipolysis such as 5-methyl-
pyrazole -3-carboxylic acid (U-19425), nicotinic acid,
uridine, inosine, 3,5-dimethylisoxazole (U-21221),
3,5-dimethypyrazole, prostaglandin E_2, eritadenine,
or eritadenine isoamyl ester; or of an agent which
inhibits lipogenesis such as ascofuranone,
(-)-hydroxycitrate, or tetrolyl-CoA; or of an agent
which is hypocholesterolemic such as lentysine; or of
an agent which lowers triglycerides such as lopid; or
of an agent which is an inhibitor of acetyl-CoA
carboxylase during lipogenesis such as 2-methyl
-2-[p-(1,2,3,4-tetrahydro-1-naphthyl)-phenoxy]-propionat
e (SU13437), 2-(p-chlorophenoxy)-2-methylpropionate,
kynurenate, xanthurenate, kynurenine, 3-hydroxy-
anthranilate, or 2-methyl-2- [p-(p-chlorophenyl)-
phenoxy] propionate; or of an agent which is an
inhibitor of hepatic B-lipoprotein production such as
orotic acid is a more efficacious hypolipidemic agent
than its free C moiety.

A luminide possessing more favorable pharmaco-
kinetics or pharmacodynamics than its C moiety of a
vasodilater such as WS-1228A, or WS-1228B; or of an

- 197 -

anti-inflammatory agent such as amicomacin A is a more
efficacious vasodilator or anti-inflammatory agent,
respectively, than the free C moiety.

A luminide with more favorable pharmacokinetics
or pharmacodynamics than its C moiety which is a
protease inhibitor such as leupeptin; or which is an
inhibitor of pepsin such as a pepstatin, a pepstanone,
or a hydroxypepstatin is a more efficacious agent for
the treatment of muscular dystrophy or peptic ulcer
disease, respectively, than its free C moiety.

A luminide with more favorable pharmacokinetics
or pharmacodynamics than its C moiety of an inhibitor
of cell surface enzymes such as bestatin, amastatin,
forphenicine, ebelactone, or forphenicin is a more
efficacious immunomodifier agent than its free
C moiety.

A luminide with more favorable pharmacokinetics
or pharmacodynamics such as enhanced permeability
relative to its C moiety of a phosphodiesterase
inhibitor such as theophyllineacetic acid, theophyl-
line, dyphylline, disodium cromoglycate, 6-n-butyl-
2,8-dicarboxy-4,10-dioxo-1,4,7,10-   tetrahydro-1,7-
phenanthrolin,   2-chloroadenosine,   dipyridamole,
EG 626, AY-17,605, AY-17,611, AY-22,252, AY-22,241,
cis-hinokiresinol,   oxy-cis-hinokiresinol,   tetra-
hydro-cis-   hinokiresinol,   trans-hinokiresinol,
dehydrodicaffeic   acid,   2,6,4'-trihydroxy-4-
methoxybenzophenone, p-hydroxyphenyl crotonic acid,
papaverine,   3-(5-tetrazolyl)-thioxanthone-
10,10-dioxide,   3-carboxythioxanthone-10,10-dioxide,
W-7,   HA-558,   MY-5445,   OPC-3689,   OPC-13135,   or
OPC-13013, reticulol, PDE-I, or PDE-II is a more
efficacious cardiac stimulant, diuretic, vasodilator,
platelett aggregation inhibitor, and an agent for the
treatment of asthma and allergic reaction than its

free C moiety. Such a luminide comprising a C moiety
of ICI 74,917 is also a more efficacious agent for the
treatment of asthma and allergic reactions.

A luminide possessing more favorable pharmaco-
kinetics or pharmacodynamics such as enhanced cellular
or blood-brain barrier permeability or resistance to
inactivation by tissue dehalogenases and transaminases
than its C functionality of an inhibitor of tyrosine
hydroxylase, the enzyme catalyzing the rate-limiting
reaction in the biosynthesis of norepinephrine, such
as azadopamine, isopropylazadopamine, dimethylaza-
dopamine; triphenolic compounds such as n-propylgal-
late; diphenolic benzoic acid derivatives such as
3,4-dihydroxybenzoic acid; phenylcarbonyl derivatives
such as 3,4-dihydroxybenzaldehyde, arterenone, or
adrenalone; H 22/54, 3-iodo-L-tyrosine, D,L-α-
methyl-p-tyrosine, L-3-iodo-α-methyltyrosine,
3-bromo-α-methyltyrosine, gentistic acid, 3-chloro-
α-methyltyrosine, phenylalanine derivatives,
3,5-diiodo- L-tyrosine, 3,5-dibromo-L-tyrosine,
3-bromo-α-methyl-L- tyrosine, 3-fluro-α-methyl-
L-tyrosine, catechol analogues, 3,4-dihydroxyphenyl-
ethylacetamide, 3,4-dihydroxyphenyliso- proplyaceta-
mide, 3,4-dihydroxyphenylbutylacetamide, 3,4-di-
hydroxyphenylisobutylacetamide, D,L-α-methylphenyl-
alanine, D,L-3-iodophenylalanine, D,L-4-iodophenyl-
alanine, D,L-α-methyl-3-iodophenylalanine,
D,L-α-methyl-3- bromophenylalanine, D,L-α-methyl-
3-chlorophenylalanine, D,L-α-methyl-3-fluoro-
phenylalanine, mimosine, mimosinamine, mimosinic acid,
7-0-methylspinochrome B, 6-(3-hydroxybutyl)-7-0-
methylspinachrome B, aquayamycin, chrothiomycin,
frenolicin, fuscaric acid, pentylpicolinic acid,
dopstatin, methylspinazarin, 6,7-dihydroxymethyl-
spinazarin, 3-ethyl-α-methyltyrosine, 3-methyl-

- 199 -

α-methyltyrosine,   3-isopropyl-α-methyltyrosine,
3-allyl-α-methyltyrosine,   3-[4-hydroxy-3-
(2-methylallyl)-phenyl]-2-methylalanine,   3-[3-(2,3-
epoxypropyl)-4-hydroxyphenyl]-2-methylalanine,
3-isobutyl-α-methyltyrosine,   3-methylvinyl-
α-methyltyrosine,   5-methyl-6,7-diphenyl-
tetrahydropterin,   3-[2,3-dihydro-2,2-
dimethyl-5-benzofuranyl]-2-methylalanine,
3-[2,3-dihydro-2,2-dimethyl-5-benzofuranyl]-2-methylalan
ine, α-methyldopa, or ethyl-3-amino-4H-pyrrolo [3,4c]
isoxazole   carboxylate   is   a   more   efficacious
antihypertensive agent than the free C moiety.

In addition, luminides which provide controlled
extracellular   release   of   biologically   active
substances such as drugs and proteins . including
enzymes and hormones are herein disclosed as
macromolecular luminides. Luminides, each comprising
a C functionality of a drug or protein such as
insulin, erythropoietin, interleuken 2, interferon,
growth hormone, atrial natriuretic factor, tissue
plasminogen activator, an anti-inflammatory drug, an
antihypertensive   drug,   an   inotropic   drug,   a
contraceptive drug, etc., are attached to a polymeric
material to which an enzyme is immobilized to form a
macromolecular luminide. The enzyme molecules react
with   molecules   in   the   ambient   extracellular
environment at a rate in proportion to their
concentration to produce peroxide or free radicals
which react with the A functionality molecules causing
them to achieve a high energy electronic state which
is followed by the release of the C molecules where
the release of C is in proportion to the ambient
concentration of the substrate of the enzyme.

For example, a macromolecular luminide which
provides a release of insulin in proportion to the

ambient glucose concentration comprises luminide
molecules, each comprising a C functionality of
insulin, covalently bound to a biocompatible polymer
to which the enzyme glucose oxidase is immobilized.
The immobilized enzyme reacts with glucose at a rate
proportional to the ambient glucose concentration to
produce peroxide which reacts with the A functionality
molecules of the attached luminide molecules to effect
release of insulin. Because the insulin release is in
proportion to the glucose concentration this
macromolecular agent represents a very effective
diabetic therapy.

     As an additional example, cardiac ischemia
results in the production and release of degradation
products of purines such as xanthine. The enzyme
xanthine oxidase oxidizes xanthine and directly
reduces oxygen to hydrogen peroxide. Furthermore,
tissue plasminogen activator (TPA) is an effective
agent for the treatment of myocardial infarction
because this agent effects the lysis of fibrin clots
in coronary arteries to establish reperfusion.
Cardiac recovery is enhanced by diminishing the delay
between the occlusion event and the administration of
TPA. Thus, a macromolecular luminide comprising
luminide molecules, each comprising a C functionality
of TPA, bound to a biocompatible polymer to which
xanthine oxidase is immobilized is an agent which
releases TPA in proportion to the products of cardiac
ischemia. Thus, it is a highly effective agent to
resolve myocardial infarctions.

     In another embodiment, luminide molecules, each
comprising an A functionality which achieves a high
energy electronic state via a reduction reaction, are
attached to a conducting polymer to which an enzyme is
immobilized. The immobilized enzyme oxidizes

molecules in the ambient environment and transfers electrons to the conducting polymer which reduces the A functionality molecules directly or indirectly via the optional D functionality molecules to effect release of the C molecules.

In the latter embodiment, the conducting polymer derivatized with an enzyme, can be replaced with an electrocatalytic polymer which is reduced directly by molecules in the ambient environment and transfers the electrons to the luminide molecules to effect release of the C molecules. For example, polyvinylferrocene and poly-[N-(9,10-anthroquinone)- ethylenimine are conductive polymers and electrocatalytically oxidize glucose. Thus, a macromolecular luminide for the treatment of diabetes comprises a conducting polymer such as polyvinylferrocene to which glucose oxidase is optionally bound and to which luminide molecules are bound where the A functionality molecules of the polymer attached luminides achieve a high energy electronic state via a reduction reaction. The polymer is reduced when glucose oxidase accepts electrons from glucose and transfers them to the polymer. Or, the electrocatalytic polymer is reduced directly by glucose. The reduced polymer reduces the A functionality molecules directly or indirectly via the optional D functionality molecules to effect release of insulin molecules in proportion to the ambient glucose concentration.

Furthermore, macromolecular luminides can be directed to a specific extracellular target site such as an anatomical or biological compartment or organ by further attaching monoclonal antibody molecules to the polymer of the macromolecular luminide which bind to a molecule at the desired target site.

- 202 -

In addition to pharmaceutical agents, luminides also comprise pesticides including herbicides, fungicides, miticides, nematocides, fumigants, growth regulators, repellants, defoliants, rodenticides, molluscicides, algicides, desicants, antehelmintics, and bactericides. These luminides can be obtained by one skilled in the art by combining the functionalities, A, B, and optionally, D, of energy donor, energy acceptor, and electron transfer functionality, respectively, with a C moiety which possesses pesticidal activity. C moieties include those that appear in Chemical Week Pesticides Register, Robert P. Ovellette and John A. King, 1977, McGraw-Hill Book Company (incorporated by reference) and analogues of these agents. Enhanced pesticidal effectiveness is acheived via improved delivery of these agents to their target receptors by way of luminide molecules which possess desirable properties such as increased permeance to the cells of the organism relative the free C moieties.

EXPERIMENTAL 2

Release Reaction

MTL 7-3 was tested for release of the nitrile group as free cyanide during the reaction of the isoluminol group with hydrogen peroxide as follows: 1.2×10^{-5} moles of 1, 5-di-(p-N-2-(N-(4-aminobutyl) -N-ethylisoluminol) -N-ethylaminophenyl) -1,5-bis-(p,N,N-dimethylaniline) -1,3-pentadiene was reacted with an excess of cyanide in a 4/4/1 DMSO/pyridine/H_2O solvent. The solution was acidified to pH one and distilled under vacuum until gas no longer evolved. The product was split into six equal aliquots of approximately one milliliter volume. A volume of .1ml of 1M NaOH was added to all aliquots. A volume of .05ml of 3% hydrogen peroxide was added to 3 of the aliquots. After five minutes cyanide was assayed following the proceedure of Gunther and Blinn.

This proceedure involves the addition of acid to the sample which is heated to distill hydrocyanic acid which is captured in a basic solution to which a colorimetric reagent is added to develop a color which is compared to a standard curve. The results are as follows:

TEST ONE

Sample	Released cyanide (ug)
Blank	0
MTL 7-3	22.2
MTL 7-3/H_2O_2	26.4

- 204 -

TEST TWO

Sample	Released cyanide (ug)
Blank	0
MTL 7-3	21.5
MTL 7-3/H_2O_2	27.0

TEST THREE

Sample	Released cyanide (ug)
Blank	0
MTL 7-3	15.0
MTL 7-3/H_2O_2	30.5

The release reaction test was repeated as follows: 4.5×10^{-6} moles of 1,5-di-(p-N-2-(N-(4-aminobutyl) -N-ethylisoluminol) -N-ethylaminophenyl) -1,5-bis-(p-N,N- dimethylaniline) -1,3-pentadiene was reacted with excess cyanide in a 1:1 DMSO/H_2O solvent. The solution was acidified to ph one and was distilled for 90 minutes under reduced pressure. The volume of the solution was made 4 milliliters by addition of H_2O. The solution was made basic by addition of 1M NaOH and was split into two equal volume aliquots. .05 milliliters of 3% H_2O_2 was added to one aliquot. Both aliquots

stood for 5 minutes, and then cyanide was determined as previously described. The results are as follows:

TEST FOUR

Sample	Released cyanide (ug)
Blank	0
MTL 7-3	73.4
MTL 7-3/H_2O_2	109.1

The results indicate that cyanide was released as a result of a reaction of hydrogen peroxide with the luminide compound. The release of lesser amounts of cyanide during the control experiment is consistent with the thermochromic properties of the luminide compound at elevated temperatures as the samples were heated during the cyanide determination proceedure.

EXPERIMENTAL 3

Efficacy of Treatment of C3H Mice Infected with Raucher Spleen Focus Forming Virus with Luminide MTL J-1.

The effectiveness of MTL J-1 was tested in C3H mice against the virus RSFFV (Raucher Spleen Focus Forming Virus) which is a retrovirus and is a valid animal model for HIV infection by application to the above identified mice according to the following procedure:

Three groups of two month old C3H mice, each comprising four animals were provided as one control and two test groups; wherein, the three groups (I-III) were subjected to an infectious dose of RSFFV on day

- 206 -

one.   The first group (I) served as control and
received no treatment. Group II and III were treated
with 10uM total body weight concentration of the drug
Foscarnet and the test compound MTL J-1, respectively
which was administered each day for days 5 through 9.
The animals were sacrificed on day 14, where upon the
spleens where removed and weighed.   The results are
summarized in the following table:

TABLE   1

	I	II	III
Ending Weight (grams)	21.1	21.2	22.5
Weight change (grams)	1.675	0.15	2.25
Spleen weight Normalized (grams)	.083	.079	.068

The tests were redone with a second control group
(IA) having no infection of RSFFV and receiving no
treatment with any drug, wherein groups I and IA
comprise four mice each, and groups II and III
comprise five mice each, providing the results
summarized below:

- 207 -

TABLE 2

	IA	I	II	III
Ending Weight (grams)	18.5	18.6	19.6	19.2
Weight change (grams)	+1.0	+1.8	+1.6	+1.5
Spleen weight Normalized (grams)	0.046	0.060	0.061	0.049

These results indicate that MTL J-1 was nontoxic as demonstrated by an absence of weight loss and that MTL J-1 was highly effective as demonstrated by the absence of splenomegaly in the animals administered this compound.

The biologically active substances not specifically mentioned are included in, and functionally applicable as a drug in the compound of the present invention. Also, the references referred to herein or filed herewith are hereby incorporated by reference. Modifications and substitutions made by one of skilled in the art are considered to be within the scope of the present invention, which is not to be limited except by the claims.

- 208 -

APPENDIX I

Triphenyl Methanes

Triphenyl methane dyes have been known and used for many years. Consequently many general-type syntheses have been worked out and published. The following four synthesis methods have been used almost exclusively for the 15 triphenyl methane dyes synthesized.

Method A.   Michler's Ketone Method

To equal molar quantities of a p-amino benzophenone or di-(p-amino) benzophenone (Michler's type ketones) and aromatic amines, such as anilines and naphthyl amines, sufficient toluene-phosphorous oxychloride solution is added (3-5) to dissolve the reactants at 50°C. The temperature is raised to 80°C and the solution is stirred for approximately 45 minutes or until the mass becomes very viscous. The sample is cooled and 10 ml of water added for each ml of phosphorous oxychloride used, and heated to boiling. The solution is cooled and treated with 6N sodium hydroxide solution until the pH is 8 or more. The sample is steam-distilled to removed the last trace of any toluene or steam volatile unreacted amine. It is cooled and the aqueous phase poured off. The organic phase is dissolved in hot methanol-acetic acid (1:1) solution. The sodium salt of the anion for the dye form desired is then added. The sample is cooled and ether added slowly, while stirring to effect crystallization of dye.

This method varies slightly from the known published methods, but has been found to have several

advantages for laboratory preparation of dyes of the types:

where any one of the phenyl groups may be replaced by a naphthyl group.

Method B. Michler's Hydrol Method

Part 1.

Triphenylmethane type compounds may be produced by the condensation of a diphenyl substituted secondary alcohol and an aromatic ring. The secondary alcohol is of a type called Michler's hydrol of the general type formula:

which is produced by the controlled reduction of the corresponding ketone with sodium amalgam in alcohol as a solvent. The hydrol is separated from an alcohol-water mixture, dried, and stored in a vacuum dessicator.

The hydrol is then condensed with the desired substituted benzene ring of the general-type formula:

in concentrated sulfuric acid and at a temperature below 60°C for several hours. The reaction mixture is diluted with water and the acid neutralized until the condensation product is precipitated out. The product has the general-type formula:

Part 2.

The condensation product is then oxidized with lead peroxide in an acidic-aqueous media to the general-type formula:

Any excess lead peroxide is neutralized with sodium carbonate. The lead is precipitated with sodium sulfate and filtered off. The acid is neutralized to a pH of 7 and the dye salted out as the chloride or as the zinc chloride double salt.

This method was found to be useful in preparing triphenyl methane dyes where one of the phenyl groups is to have substituents other than an amino group.

- 212 -

APPENDIX II

Method C. Aniline – Benzaldehyde Method

Under reflux, a two-mole quantity of an aniline and one mole of a benzaldehyde is heated with zinc chloride as a catalyst to produce the true leuco form of the desired dye.

A stoichiometric quantity of lead dioxide paste and hydrochloric acid is added to a weighed quantity of the leuco dye. This is stirred for 30 minutes and then filtered. Sodium sulfate is added to precipitate any soluble lead salts, which is then filtered and the filtrate neutralized. A neutral salt is added to salt out the dye. (The salt chosen for salting out will depend on the anion form of the dye desired.)

Method D. Alkyl Halide Method

Dyes of the type

may be reacted with alkyl iodides in an alkaline
methanol solution to replace the hydrogen on each
amino group with the alkyl group of the alkyl iodide
to yield dyes of the type:

of the 15 triphenyl methan dyes synthesized, 6 were
found to be phototropic and were previously tabulated
under 3.2.6.1.   For   the   other   nine dyes,   no
phototropic systems have yet been developed.

Polymethines

    Polymethines   (refs. 13,   18,   19)   may   be
classified generally by the degree of symmetry around
the   conjugated   carbon   chain.   If we represent the
polymethines by the general formula:

we may further classify the dyes on the basis of the
identify of the various R groups.   It is prerequisite
to this family that at least two of the R groups be

capable of extending the conjugation of the chain by accepting a positive charge,

being such a group.

Where R_1 and R_4 meet the prerequisite of the family and either R_2 or R_3 or both are hydrogen, the dyes may be prepared by methods I and II of the four general methods given in the succeeding pages.

Where R_4 is hydrogen and R_1, R_2 and R_3 are other than hydrogen and at least two of them meet the prerequisite of the family, the dyes may be prepared by methods I or IV.

Where none of the R's are hydrogens, the dyes may be prepared by methods II or III; the choice of method will depend on the value of n and the degree of symmetry desired. When the value of n is to exceed 1, method III cannot be used. Method III has the advantage of giving any choice of symmetry from totally unsymmetrical to totally symmetrical, but the value of n is limited to 1.

Method I.   Reaction of a p-aminophenyl alkene and
                   a p-aminophyenl alkene aldehyde

Equimolar quantities of a p-aminophenyl alkene of the class

(where R_a can equal H, aryl, alkyl, or arylamine groups) and p-aminophenyl alkene aldehyde of the class

$$>N-\bigcirc-[CH=CH]_n CHO$$

WHERE N=0,1

(where n=0,1) are allowed to react in a nonaqueous solvent with an acid catalyst such as acetic acid, or acetic anhydride, and the acid of the desired dye form. The reaction mixture is allowed to stand for 5 days at room temperature. This is poured into water and neutralized until the dye precipitates. The precipitate is filtered off, dried, and recrystallized from anhydrous alcohol. This will produce a dye of the general-type formula as depicted below:

$$>N-\bigcirc-\underset{\underset{R_a}{|}}{C}=CH[CH=CH]_n-CH=\bigcirc=\overset{+}{N}<$$

- 216 -

Method II.   Reaction of p-Aminophenyl
            alkene and an Orthoester

Method IIa.

(for compounds having 5 or more methine carbon atoms)

Two molar proportions of a p-aminophenyl alkene of the class

$$>N\!\!-\!\!\!\bigodot\!\!-\!\!\underset{\underset{R_b}{|}}{C}\!=\!CH_2$$

(where R_O can equal H, aryl, alkyl, or arylamine group) with one mold of an orthoester of the class

$$\underset{\underset{OR}{|}}{CH}[=CH\!-\!CH]_n\!\!\begin{array}{c}\nearrow OR\\ \searrow OR\end{array}$$

WHERE N=0,1,2, OR 3

(where m=0, 1, 2, or 3) are allowed to react in a nonaqueous solvent, containing an acid catalyst such as acetic anhydride and the acid to form the desired carbonium compound. The reaction mixture is allowed to stand at room temperature for several hours. Ether is added to precipitate the dye. The precipitate is filtered and washed with ether or an ether-polar solvent mixture. The precipitate is

dried in vacuum. This will produce a compound of the general-type formula as pictured below:

(where n=0, 1, 2, 3, or 4).

Method IIb.

By substituting tetramethyl ortho carbonate for the orthoester of method IIa and by increasing the p-aminophenyl alkene to a molar proportion of three, a new type of compound was prepared, having the general structure:

A nitrogen determination on

using a Coleman nitrogen analyzer found 8.58 percent
nitrogen (theoretical 8.61).

Method III.   Reaction of a Ketone and a
1-(p-Aminophenyl)-1-(R) Alkene

A ketone of the general-type formula

is refluxed with a substituted alkene, of the general-type formula

$$\text{>N} - \bigcirc - \underset{\underset{C-R}{\|}}{CH_2}$$

where R is something other than hydrogen with phosphorous oxychloride as the solvent catalyst. At the end of the reflux, the reaction mixture is cooled and poured into water and treated with a salt of the acid to yield the desired anion form of the dye. The aqueous mixture is neutralized with solid sodium acetate until the dye precipitates.

This method yields a dye of the general-type formula

$$\left[\text{>N} - \bigcirc - \underset{\underset{R_b}{|}}{\overset{\overset{R_a}{|}}{C}} = CH - C = \bigcirc = \overset{+}{N} \!< \right]$$

where R_a and R_b may be equal or different.

Method IV.   Reaction of a Ketone and
a p-Aminophenyl Alkene

A ketone of the general-type formula

is refluxed for 5 hours with a substituted alkene of the general-type formula

with phosphorous oxychloride as a solvent catalyst. At the end of the 5-hour reflux time, the reaction mixture is cooled and poured into water and treated with a salt of the acid to yield the desired anion form of the dye. The aqueous mixture is neutralized with solid sodium acetate until dye precipitates.

This method yields a dye of the general-type formula:

where R_a and R_b may be equal or different.

Organic Synthesis Procedures

Method No. 1:   Polymethine dyes
Example: Preparation of dye PP 2109

Step A: Preparation of p-Fluorobenzanilide

A solution of aniline, 23.7 g (0.255 mole) in
250 ml of dry ether containing 55.3 g of potassium
carbonate was heated to reflux temperature. To the
refluxing mixture, 50 g (0.32 mole) of p-fluoro-
benzoyl chloride was added over a period of
one hour. The reaction mixture was refluxed for
four hours and the ether distilled off. Cold water
was added to the residue and the p-fluorobenzanilide
collected by filtration. Yield: 64 g, metling point
196°C, white crystalline powder.

Step B: Preparation of
p-N,N-Di-n-propylamin-p-fluorobenzophenone

64 g (0.3 mole) of dry, powdered p-fluorobenzanilide, 100 g (0.6 mole) of N,N-di-n-propylaniline, and 55 ml of phosphorous oxychloride were mixed in a 500 ml three-necked flask fitted with a stopper, a thermometer and a reflux condenser having a $CaCl_2$ drying tube on top. The reaction mixture was warmed gently until the temperature reached 100°-112°C, at which point an exothermic reaction occurred and the temperature rose to 160°C. As soon as the exothermic reaction was noted, the mixture was immediately cooled by swirling the flask in ice water. The cooling was continued until the temperature dropped to 100°-105°C. This temperature range was held for three hours. The reaction mixture was then hydrolyzed in a three liter beaker by the addition of 58 ml concentrated hydrochloric acid in 445 ml water. The reaction mixture was allowed to stand for eight to twelve hours to complete the hydrolysis. An additional 4100 ml of water was then added to precipitate the ketone formed. This was filtered, washed thoroughly with cold water, reslurried and refiltered. Yield: 45 g, light green sandy crystals, melting point 85°-87°C.

Step C: Preparation of
1-(4-N,N-Di-n-propylamino-phenyl)-1-(4-fluorophenyl)
ethylene

Sixty ml of a 3 molar etherial solution of methyl magnesium bromide was evaporated almost to dryness under reduced pressure in a 500 ml three-necked flask equipped with thermometer and nitrogen sparger. The grey moist residue was suspended in 75 ml of dry benzene. The flask was then equipped for refluxing by the addition of a condenser fitted with a $CaCl_2$ drying tube and an addition funnel. A 0.1 mole portion of the ketone dissolved in 250 ml of boiling benzene was then placed in the addition funnel and added dropwise to the warmed methyl magnesium bromide-benzene slurry over a half-hour period. The resulting reddish solution was refluxed for three hours. The termination of the reaction was indicated by the fading of the initial reddish color to a pale yellow. The reaction mixture was then cooled to room temperature and cautiously treated with 45 ml of saturated ammonium chloride solution. This mixture was filtered and the filtrate boiled with 0.1 g of p-toluenesulphonic acid until the evolution of water was completed. The acid contained in the reaction mixture was then removed by the addition of 0.5 g of sodium bicarbonate. The volume was reduced to one half by evaporation under reduced pressure. Five hundred ml of dry ethanol was added to the remaining solution, which was then allowed to cool with the subsequent precipitation of the ethylene compound. The precipitate was filtered, washed with 50 ml ice cold ethanol, and the crystals dried in a vacuum oven. Yield: 86 percent of theory: melting point 101°-102°C.

- 224 -

Step D: Preparation of a perchlorate of
1,5-di-(p-fluorophenyl)-1,5-bis-(p-N,N-di-n-propyl-
anilino)-1,3-pentadiene

A mixture of 23.6 g (0.08 mole) of 1(4-N,N-di-n-
propylaminophenyl)-1-(4-fluorophenyl)ethylene,   12 ml
of ethyl orthoformate and 50 ml of acetic anhydride
was treated with an ice-cold solution of 4 ml of
72 percent perchloric acid dissolved in 50 ml of
acetic anhydride. The resulting dark red solution
was heated in a water bath at 85°C for one hour,
after which another 12 ml of ethyl orthoformate was
added. The mixture was than allowed to stand at room
temperature   for   18 hours   to   precipitate   the
condensation product. The precipitate was collected
and washed with acetic acid, ethanol and ether.
Yield: 68 percent based on perchloric acid, golden
brown crystals melting with decomposition at 277°C.

- 225 -

Method No. 2:   Polymethine dyes

Example: Preparation of dye PP 2110

Step A: Preparation of

3-Amino-4-methoxy-4'-N,N-Di-methylaminobenzophenone

Fifty grams (0.2 mole) of 3-amino-4-methoxy-benzanilide, 70 g (0.58 mole) N,N-dimethylaniline and 36 g $POCl_3$ were heated on a water bath at 90°C to 95°C for 4 to 6 hours. The product was then cautiously poured into a solution of 23 ml of concentrated hydrochloric acid in 250 ml water. The resulting solution was warmed at 80°C until the initial reddish color disappeared, indicating that the aniline was completely hydrolyzed. A liter of water was added to precipitate the ketone, which was filtered, washed with cold water, and recrystallized from a 2:1 aqueous alcohol solution. Yield: 38 g of slightly yellowish crystals, metling point 82°C.

Step B: Preparation   of   1(4-N,N-Dimethylamino-
phenyl)-1-(3-amino-4-methoxyphenyl)ethylene

Fifty ml of a 3 M ethereal solution of methyl
magnesium bromide was evaporated almost to dryness
under reduced pressure. Dry nitrogen was admitted to
the reaction flask and the gray residue was suspended
in 75 ml of dry benzene. The slurry was warmed, then
26.6 g (0.1 mole) of the ketone compound dissolved in
250 ml boiling benzene was added over a 15-minute
period. The resulting solution was refluxed until
the pale yellow color faded to colorless
(45 minutes). The mixture was cooled and treated
with 50 ml of a saturated NH$_4$Cl solution. The
colorless solution was filtered through a folded
filter paper without applying vacuum and in the
absence of strong light. The filtrate was boiled
with 0.1 g p-teluenesulfonic acid until the evolution
of water was complete. The cooled solution was
neutralized by the addition of 0.2 g dry NaHCO$_3$ and
then reduced to 1/4 volume by evaporating the solvent
under reduced pressure. The remaining solution was
diluted with 250 ml of dry ethanol and the ethylene
product allowed to precipitate over 12 hours.
Yield: 34 percent of theory, yellow hygroscopic
flakes, melting point 118°C.

- 227 -

Step C: Condensation Reaction Leading to Dye (A perchlorate of 1,5-di-(3-amino-4-methoxyphenyl)-1,5-bis-(p-N,N-dimethylaniline)-1,3-pentadiene.

A mixture of 26.9 g (0.1 mole) of 1(4-N,N-dimethylaminophenyl)-1-(3-amino-4-methoxyphenyl)ethylene, 15 ml of ethyl orthoformate and 45 ml acetic anhydride was treated with a solution of 4 ml of 72 percent perchloric acid and 40 ml acetic acid previously cooled to 0°C. The resulting mixture was allowed to stand at room temperature for 5 days, after which it was treated with 25 ml of ether and kept an additional day at room temperature. The precipitate formed was filtered and washed with acetic acid, ethanol, and ether, and dried in a vacuum dessicator.

Product: sandy crystals, dark brown, melting point 209°-210°C.

Note: The reaction should be run at room temperature. Condensation at elevated temperatures yields a black, insoluble polymerization product.

- 228 -

APPENDIX III

Azo Polymethines

Dyes of the general structural type

are prepared by condensation of p-aminophenyl alkene aldehydes or ketones with auramine-type hydrochlorides. One such dye was prepared:

1,1,5-tris-4(N,N-dimenthyamino)phenyl-2-azo; pentene carbonium chloride which showed only very slight yellow phototropy.

APPENDIX IV

Diazo Polymethines

A new type of dye, believed to have the general structures,

C—N≡N—C=C

was prepared by nitrosation of auramine-type structures

C=NH

with nitrous acid to yield

C=N—N=O

This is then reacted with p-aminophenyl alkenes to yield structures of Type A. Confirmation of structure is incomplete, but significant to this work is that the above series of reactons yield phototropic materials.

The position of the -N-N- group in the carbon chain may be changed to occupy the 1 and 2 positions, as well as the above shown 2 and 3 positions, by using a secondary amine in place of B in the above series of reactions. With nitrogen atoms in the 1

- 230 -

and 2 positions, the 1 position nitrogen becomes a
quaternary ammonium atom in one of the resonance
states of the molecule.

One dye of each of these types was prepared.
Both were found to phototropic. They are:

1,1,5,5-tetrakis-[4-(N,N-dimethylamino)phenyl]-2,3-
diazo pentene carbonium (Code PP2031)

1,1-bux-[4-(N,N-dimethylamino)phenyl-3,4-bis-(phenyl)]-
3,4-diazo butene carbonium (Code PP 2030)

- 231 -

APPENDIX V

<u>Quaternary Ammonium Salt Polymethines</u>

Three dyes of the type

were prepared and tested for phototropy.

N-(p-dimethylamino cinnamylidine)-N,N-diphenyl
ammonium proved to be phototropic but broke down
rapidly under ultraviolet light

N-(p-dimethylamino cinnamylidine)-N,N-diethanol
ammonium, and

N-(p-dimethyl amino cinnamylidine)
N,N-di-4(N,N-dimethylamino)phenyl ammonium were not
phototropic.

- 232 -

The dyes where prepared by the condensation of dimethylamino cinnamic aldehyde with the hydro-chloride of secondary amines in warm, anhydrous alcohol according to the method of Brooker.

- 233 -

APPENDIX VI

Intermediates

Although most types of dye intermediates are available, specific compounds necessary to this work were not available on the commercial market. It was necessary to synthesize 13 such intermediates.

The syntehsis or type synthesis of these intermediates are for the most part given in standard works on synthesis dyes and dye intermediates.

The synthesis of tetramethyl orthocarbonate and ethylenes of the type are reported herein.

Synthesis of Tetramethyl Ortho Carbonates

To 500 grams of cold dry methanol under reflux, 80 grams of metallic sodium in large pieces are added. (The alcohol solution has to be cooled externally with ice water to prevent loss of methanol through the reflux condenser.) Before all of the sodium has dissolved, 100 grams of chloropicrin that has been diluted with 200 ml of methanol is slowly dropped in. The solution is refluxed for one hour. The methanol is distilled off until the residue seems almost dry. This is then dissolved in 600 cc of water, and the aqueous solution is extracted with three 200-ml portions of ether. The composited ether extracts are dried over calcium chloride. The ether is fractionated from the dried solution and a little sodium methoxide in methanol is added to the residue to react with any unreached chloropicrin. This is allowewd to stand overnight. The solution is

- 234 -

fractionated, collecting one fraction between 110°-115°C.

Synthesis of $\rangle H-\bigcirc-\underset{\underset{Al}{|}}{C}=CH_2$ Type Ethylenes

Methyl magnesium bromide in ethyl ether is placed into a round bottom flask equpped with a condenser and an addition funnel. The ther is distilled off, and the methyl magnesium bromide then taken up with anhydrous benzene. A ketone is dissolved in anhydrous benzene and added dropwise to the Grignard reagent with continuous heating. After the addition is completed, the mixture is refluxed for three more hours. After cooling, sufficient ammonium chloride solution (saturated aqueous solution) is very carefully added in order to dissolve any free magnesium. The Grignard complex is decomposed with hydrochloric acid. After decomposition of the complex is complete, the solution is allowed to come to room temperature. After making sure the solution is alkaline to phenolphthalein, the benzene solution is decanted off of the solids. The solids are washed with two 50-ml positions of ether and the washings combined with the benzene solution. The ether-benzene solution is dried over anhydrous sodium sulfate.

The ether and benzene are then distilled off leaving a residue. This residue is vacuum-distilled at 2-5 mm of Hg.

– 235 –

APPENDIX VII

Method No. 3: Indoline base dyes
Example: Preparation of dye PP 1210
Step A: Synthesis of
p-[N-(2-chloroethyl)-N-ethyl]aminobenzaldehyde

- 236 -

At 50°C 82.5 parts by weight of N-(2-hydroxyehtyl)-N-ethylaniline were added dropwise to 90 parts by weight of phosphorous oxychloride. The solution was then heated at 90°C for 6 hours. After colling to 0°C, a mixture of 150 parts by weight of N-methylformanilide, 170 parts by weight of phosphorus oxychloride, and 120 parts by weight of benzene was added to the above solution. The mixture was heated for a few hours at 30-35°C. After neutralization with an aqueous solution of sodium hydroxide, the benzene solution of the aldehyde product was separated. After evaporating the benzene, p-N-chloroethyl-N-ethylamino benzaldhyde remained as a slightly yellow oil which hardened on standing and could be recrystallized from ethanol. The recrystallized aldehyde had a white flaky appearance and a melting point of 283°C.

Step B: Synthesis of dye PP 2120, Chloride of 2,3,3-trimethyl-2-[p-(N-2-chloroethyl-N-ethyl)amino-ß-s tyryl] indoline.

- 238 -

p-(N-Chloroethyl-N-ethyl)amino   benzaldehyde
(12.5 parts by weight) was refluxed for 6 hours at
100°C   with   8.5 parts   by   weight   of
1,3,3-trimethyl-2-methylene-indoline in 60 parts by
weight of glacial acetic acid. The mixture was then
poured into water and the condensation product was
salted out with sodium chloride. The crude dyestuff
was obtained as a dark bronze resinous liquid which
hardened upon standing and could be crushed into
shiny bronze particles. The pure dye was obtained by
recrystallization from hot water, m.p. 167-168°C.

APPENDIX VIII

Method No. 4: Dyes with more than one chromophore
Example: Preparation of dye PP 2131
Step A: Synthesis of phenetolazobenzaldehydsulphonic
acid

One hundred grams of Chrysophenin G concentrate,
which was equivalent to about 92 grams of the pure
compound, was dissolved in 6 liters of boiling
water. The solution was cooled to 0-5°C by the
addition of ice and then saturated with sodium
chloride.

Chrysophenin G

OC_2H_5

SO_3Na

$CH = CH$

SO_3Na

$N = N$

C_2H_5O

$\xrightarrow{KMnO_4}$

OC_2H_5

$N = N$

OHC

KO_3S

$C=CH_2$

$(CH_3)_2N$

$(CH_3)_2N$

$\xrightarrow{HOAc}$

$\left[\quad \right]^{+} ClO_4^{-}$

OC_2H_5

$N = N$

HO_3S

$CH=CH$

C

$(CH_3)_2N$

$(CH_3)_2N$

- 241 -

A 3 percent solution of potassium permanganate was slowly added with vigorous agitation until a pale pink color persisted. (The quantity of permanganate required was 29 grams.) The precipitate which formed during the reaction was allowed to settle and was collected by siphoning off the supernatant liquor. The product was isolated by boiling the precipitate two or three times with one liter of water, filtering off the manganese dioxide and adding potassium chloride to the hot water solution until precipitation was complete. An additional small quantity of aldehyde was isolated by salting it out of the supernatant liquor with potassium·chloride. The product precipitated from water in orange-colored microscopic needles.

Step B: Synthesis of Dye PP 2131, perchlorate of 1,1-bis-(p-N,N-dimethylamino)phenyl-3-[2-sulfonato-4-(p-ethoxyphenylazoO] phenyl propene.

Phenetoleazobenzaldehyde sulphonic acid (1.86 parts by weight) was refluxed for 6 hours at 100°C with 1.33 parts by weight of 1,1-bis-(4-N,N-dimethylamino)phenyl ethylene is 25 parts by weight of glacial acetic acid. The condensation product was then poured into water and salted out. The dyestuff was obtained as a thick dark green liquid which hardened upon standing to a crushable solid, melting point 78-92°C. An attempt to recrystallize the dye using a variety of solvents was unsuccessful.

- 242 -

APPENDIX IX

Example 1 - Xylene Blue VS cyanide

To a solution of 25 g. of commercial Xylene Blue
VS, Colour Index No. 672, in 150 ml. of water is
added 4.5 g. of 95% sodium cyanide and the mixture is
heated in a pressure bottle for 1 hour. Suitable
precautions should be taken to avoid cuts by glass
wet with sodium cyanide solution in the event of the
explosion of the bottle. The solution is then
cooled, allowed to stand for 1 day at 25°C. and
filtered from the precipitated Xylene Blue VS cyanide
disodium salt having the formula

$$N[C_2H_5]_2 \quad SO_2Na \quad N[C_2H_5]_2$$

$$SO_2Na$$

$$C$$

$$CN$$

The disodium salt is readily soluble in water to
yield a colorless solution that slowly becomes blue
on exposure to radiation of wave length 2537 A. The
color change is much slower than with a solution of a
representative basic dye cyanide, such as malachite
green syanide in alcohol, and thus is useful in the
actinometry of more intense radiation.

The free acid form of Xylene Blue VS cyanide, having the formula

may be prepared by treatment of a solution of 11 g. of the disodium salt in 100 ml. of water with 11.2 ml. of concentrated hydrochloric acid. After the mixture has stood at room temperature for 2 days, the colorless precipitated from acid is collected on a filter, washed with water, and air dried. It is sparingly soluble in water. A dilute, colorless, aqueous solution of the free acid color blue on ultra-violet irradiation at a speed intermediate between that of the solutions of the sodium salt and of alcoholic solutions of malachite green cyanide.

The barium salt of Xylene Blue VS cyanide having the formula

may be prepared by neutralization of a hot 1/2 of 1% aqueous solution of the free acid to pH 3.4 with N/10 barium hydroxide solution. The neutralized solution is cooled to room temperature, allowed to stand for 3 days, and filtered from the colorless, crystalline barium salt. The barium salt is less soluble in water than the free acid, but quite sufficiently soluble to give photosensitive solutions that behave on exposure to ultra-violet like solutions of the sodium salt.

- 245 -

References

1. Schuster, G.B., Schmidt, S.B., <u>Bioluminescense and Chemiluminescence</u>, edited by Marlene A. Deluca and William D. McElroy, (1981), pp. 23-29.

2. Berger, A.W., et al., Photochemistry and Photobiology, Vol. 4, (1965), pp. 1123-1127.

3. Philbrook, G.E., et al., Photochemistry and Photobiology, Vol. 4, (1965), pp. 1175-83.

4. White, E.H., et al., Photochemistry and Photobiology, Vol. 4, (1965), pp. 1129-55.

5. Philbrook, G.E., et al., Photochemistry and Photobiology, Vol. 4, (1965), pp. 869-76.

6. Rauhut, M.M., et al., Photochemistry and Photobiology, Vol. 4, (1965), pp. 1097-1110.

7. McCapra, F., et al., Photochemistry and Photobiology, Vol. 4, (1965), pp. 1111-1121.

8. McCapra, F., et al., Chemical Communications, No. 15, (1966), pp.522-23.

9. Gorsuch, J.D., "Studies of the Chemiluminescence of Luminol," M.I.T. Ph.D. Thesis, 1969.

10. Legg, K.D., "The Chemiluminescence of Lucigenin," M.I.T. Ph.D. Thesis, 1969.

- 246 -

11. Lytle,   F.E.,   "Chemiluminescence   and
     Photoluminescence of Ruthenium Chelates," M.I.T.
     Ph.D. Thesis, 1968.

12. Allen, R.C., _Chemical and Biological Generation
     of the Excited State_, edited by Adam Waldeman,
     1982, pp. 309-45.

13. Bowen, E.J., "Chemiluminescence in Solutions," in
     Luminescence in Chemistry, Edited by E.J. Bowen,
     D. Van Nostrand Co. Ltd, London, (1968) pp.
     183-190.

14. Tuemmler, W.B., and Widi, B.S., J Amer Chem Soc,
     Vol. 80, (1958), pp. 3772-75.

15. Mac Nair, R.N., Photochemistry and Photobiology,
     Vol. 6, (1967), pp. 779-97.

16. Chalkley, L., U.S. Patent No. 2,885,303, (1958).

17. Chalkley, L., U.S. Patent No. 2,936,235, (1957).

18. Chalkley, L., U.S. Patent No. 2,829,148, (1958).

19. Chalkley, L., U.S. Patent No. 2,839,542, (1958).

20. Chalkley, L., U.S. Patent No. 2,839,543, (1958).

21. Brown, Glenn, _Photochromism_, pp. 294-375.

22. Wilkinson, F., "Intramolecular Electronic Energy
     Transfer   Between   Organic   Molecules,"   in
     Luminescence in Chemistry, Edited by E. J. Bowen,
     D. Van Nostrand Co. LTD., London, (1968), pp.
     154-182.

- 247 -

23. Lippman, R.D., Bioluminescence and Chemiluminescence, Edited by Marlene A. Deluca and William D. McElroy, (1982), pp. 373-81.

24. Dreyer, J.F., "Self-Attenuating Ophthalmic Filter," Rept. WADD-TR-60-632 Feb., 1961. AD 322820.

25. Dreyer, J.F., Harries, R.W., MacNair, R.N., Feldman, D., "Investigation of Materials and Systems for Protection Against Flash Blindness Effects of Nuclear Detonations," Rept. 68-38-CM, AD 688692.

26. Polacoat, Inc., "Development of a Means to Provide Protection for Eyes Against the Dazzle Effects of Nuclear Detonations," Quart. Rept. No. 5 on Contract DA-19-129 qm-1534, April 1961, AD 446865; also AD 447113 and 298225.

27. Van Dyke, K., Bioluminescence and Chemiluminescence, Vol. 1, CRC Press, Inc., 1985, pp. 1-42.

28. Zaklike, K.A., et. al., Photochemistry and Photobiology, Vol. 30, (1979), pp. 35-44.

29. Schaap, A.P., Burns, P.A., and Zaklika, K.A., J. Am. Chem. Soc., 99 (1977), pp. 1270-1272.

30. D'Iorio, A., Mavrides, C., Canadian Journal of Biochemistry and Physiology, (1963), Vol. 41, pp. 1779-1784.

- 248 -

31. Vrang, L., Oberg, B., Antimicrobial Agents and Chemotherapy, (1986), 29, pp. 867-872.

32. Schnebli, H.P., et. al., Journal of Biological Chemistry, (1967), Vol. 242, pp. 1997-2004.

33. Roberts, E., Biochemical Pharmacology, (1974), Vol. 23, pp. 2637-2649.

34. Rando, R., Bangerter, F. W., Journal of the American Chemical Society, (1976), Vol. 98, pp. 6762-6764.

35. Tunnicliff, G., et. al., Experientia, (1977), Vol. 33, pp. 20-22.

36. Kobayashi, K., et. al., Febs Letters, (1977), Vol. 76, pp. 207-210.

37. Medicinal Chemistry A Biochemical Approach, Thomas Nogrady, (1985) Oxford University Press, N.Y., N.Y., pp. 193-203.

38. Jung, J.M., Metcalf, B.W., Biochemical and Biophysical Research Communications, (1975), 67, pp. 301-306.

39. Rando, R., Bangester, F.W., Biochemical and Biophysical Research Communications, (1977), Vol. 76, pp. 1276-1281.

40. Buu, N.T., Van Gelder, N.M. Br. J. Pharmac, (1974), 52, pp. 401-406.

- 249 -

41. Enzyme Inhibitors, edited by Urs Brodbeck, (1980) pp. 85-95.

42. Enzyme Inhibitors, ed. by Urs Brodbeck, (1980), pp. 61-74.

43. Drug Action and Design: Mechanism Based Enzyme Inhibitors, ed. by Kalman,, (1979), pp. 13-27.

44. Fuller, R.W., Nagarajan, R., Biochemical Pharmacology, (1978) pp. 1981-1983.

45. Barchardt, R.T., Wu, Y.S., Journal of Medicinal Chemistry, (1975), 18, pp. 300-303.

46. Enzyme Inhibitors, ed. by Urs Brodbeck, (1980), pp. 223-244.

47. Receptor Binding in Drug Research, ed. by Robert A. O'Brien, pp. 235-259.

48. Kandutsch, A.A., Chen, H.W., Journal of Biological Chemistry, (1973), 248, pp. 8408-8417.

49. Fimognari, G.M., Rodwell, V.W., Biochemistry, (1965) 4, pp. 2086-2090.

50. Bloxham, D.P., Biochem J., (1975), 147, pp. 531-539.

51. 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase, ed., by John R. Sabine, CRC Series in Enzyme Biology, CRC Press, Inc. Boca Raton, Florida.

- 250 -

52. <u>Design of Active-Site-Directed Irreversible Enzyme Inhibitors</u>, B.R. Baker, (1975), p. 9.

53. <u>Inhibitors of DNA and RNA Polymerases</u>, International Encyclopedia of Pharmacology and Therapeutics, Section 103, edited by Prem S. Sarin and Robert C. Gallo, Pergamon Press, N.Y., N.Y.

54. Mao, J.C., Robishaw, E.E., Biochemistry, (1975), 4, pp. 5475-5479.

55. Layton, D., Azzi, A., Biochemical and Biophysical Research Communications, (1974) 59, pp. 322-325.

56. Saari, W.S., et. al., J. Am. Chem. Soc., (1967), 10, pp. 1008-1014.

57. Bergstrand, H., et. al., Molecular Pharmacology, (1977), 13, pp. 38-43.

58. Fuller, R.W., et. al., Journal of Medicinal Chemistry, (1975), 18, p. 304.

59. Bricker, L.A., Levey, G.S., Journal of Biological Chemistry, (1972), 247, pp. 4914-4915.

60. Khwaja, T.A., et. al., Biochemistry, (1975), 14, pp. 4238-4244.

61. Bertelli, A., et. al., Experientia, (1976), 32, p. 361-362.

- 251 -

62. <u>Medicinal Chemistry A Biochemical Approach</u>, Thomas Nogrady, (1985) Oxford University Press, N.Y., N.Y., pp. 274-285.

63. <u>Prostaglandin Synthetase Inhibitors: New Clinical Applications</u>, (1980) Alan R. Liss Inc., N.Y., N.Y., pp. 231-256.

64. <u>The Pharmacological Basis of Therapeutics</u>, ed. by A.G. Gilman, L. Gilman, 6th ed., (1980) MacMillan Publishing Co., N.Y., N.Y., pp 668-681.

65. Way, L., Durbin, R.P., Nature, (1969), 221, pp. 874-875.

66. Kattlove, H.E., Biochimica et. Biophysica Acta, (1974), 372, pp. 135-140.

67. <u>Medicinal Chemistry A Biochemical Approach</u>, Thomas Nogrady, (1985), Oxford University Press, N.Y., N.Y., pp 358-361.

68. Porter C.C., Watson, L.S., J. Am. Chem. Soc., (1967), 10, pp. 852-855.

69. Sourkes, T.L., Arch. Biochem. Biophys., (1954), 51, pp. 444-456.

70. Hartman, W.J., et. al., J. Biol. Chem., (1955), 216, pp. 507-529.

71. Collins, K.D., Stark, G.R., Journal of Biol. Chem. (1971), 246, pp. 6599-6605.

- 252 -

72. Lienhard, G.E., Science, (1973), 180, pp. 149-154.

73. Fall, R.R., West C.A., Journal of Biol. Chem., (1971), 246, pp. 6913-6928.

74. Coleman, J.E., Journal of Biol, Chem., (1968), 243, pp. 4574-4587.

75. Agarwal, R.P., et. al., Biochemical Pharmacology, (1975), 24, pp. 693-701.

76. Agarwal, R.P., et. al., Biochemical Pharmacology, (1977) 26, pp. 359-367.

77. Sheen, M.R., et. al., Mol. Pharmacol., (1968), 4, pp. 293-299.

78. Analysis of Insecticides and Acaricides, Gunther and Blinn, (1955), Interscience, N.Y., N.Y., pp. 401-404.

79. The Pharmacological Basis of Therapeutics, ed., by A.G. Gilman, L. Goodman, A. Gilman, 6th ed., (1980), MacMillan Publishing Co., N.Y., N. Y.

80. Berridge, M.J., Ann. Rev. Biochem., (1987), 56, pp. 159-93.

81. Calcium Antagonists and Cardiovascular Disease, edited by L. H. Opie, (1984), Raven Press, N. Y., pp. 165-173.

82. Johnston, G.A.R., Iversen, L.L., Journal of Neurochemistry, (1971), 18, pp. 1951-1961.

- 253 -

83. Chiou, C. Y., Malagodi, M. H., Br. J. Pharmac., (1975), 53, 279-285.

84. Inagaki, M., et. al., J of Biol. Chem., (1985), 260, pp. 2922-2925.

85. Inagaki, M., et. al., Biochemistry, (1984), 23, 5036.

86. Weinstock, M., Life Sciences, (1976), 19, pp. 1453-1466.

87. Hare, L.E. et. al., Journal of Medicinal Chemistry, (1974), 17, pp. 1-5.

88. Levitt, M., et. al., Biochemical Pharmacology, (1972), Vol. 16, pp. 1313-1321.

89. Nagatsu, T., et. al., Biochemical Pharmacology, (1972), Vol. 21, pp. 1945-1953.

90. Taylor, R.J., et. al., Biochemical Pharmacology, (1968), 17, pp. 1779-1788.

91. Nagatsu, T., et. al., J. Biol. Chem., (1964), 239, pp. 2910-2917.

92. Taylor, R.J., Ellenbogen, L., Life Sciences, (1967) 6, pp. 1463-1466.

93. Undenfriend, S., et. al., Biochemical Pharmacology, (1965), 14, pp. 837-845.

94. Weinhold, P.A., Rethy, V.B., Biochemical Pharmacology, (1969), 18, pp. 677-680.

- 254 -

95. Uretsky, N.J., et. al., The Journal of Pharm. and Exp. Therp., (1975), 193, pp. 73-87.

96. El Masry, M.H., et. al., Journal of Medical Chemistry., (1975), 18, pp. 16-20.

97. Counsell, R.E., et. al., Journal of Medical Chemistry, (1970), 13, pp. 1040-1042.

98. Robert, A., et. al., Life Sciences, (1974), 14, pp. 533-538.

99. Kollonitsch, J., et. al., Nature, (1978), 274, 906-908.

100. Polakoski, K.L., McRorie, R.A., Journal of Biol. Chemistry, (1973), 248, pp. 8183-8188.

101. Way, L. Durbin, R.P., Nature, (1969), 221, pp. 874-875.

102. Lippmann, W., Seethaler, K., Experientia, (1973), 29, pp. 993-995.

103. Lippmann, W., Experientia, (1973), 29, pp. 990-991.

104. Chen, F.W.K., et. al., Prostaglandins, (1977), 13, pp. 115-125.

105. Hidaka, H., Nautre, (1971), 231, pp. 54-55.

106. Hidaka, H., et. al., Mol. Pharm., (1973), 9, pp. 172-177.

107. Van Der Schoot, J.B., et. al., Journal of Pharm. Exp. Therp., (1963), 141, pp. 74-78.

108. Hidaka, H., et. al., Journal of Pharm. Exp. Therp., (1974), 191, pp. 384-392.

109. Johnson, G.A., et. al., Journal of Pharm. Exp. Therp., (1969), 168, pp. 229-234.

110. Nagastu, T., et. al., Experientia, (1972), 28, pp. 779-780.

111. Lippmann, W., Lloyd, K., Biochemical Pharmacology, (1969), 18, pp. 2507-2516.

112. Diliberto, E.J., et. al., Biochemical Pharmacology, (1973), 22, pp. 2961-2972.

113. Porter, C.C., Torchiana, M.L., Biochemical Pharmacology, (1971), 20, pp. 183-191.

114. Oyama, H., et. al., Biochemical Pharmacology, (1976), 25, pp. 277-280.

115. Catignani, G.L., Neal, R.A., Life Sciences, (1975), 16, 1915-1922.

116. Hashiguchi, H., Takahashi, H., Mol. Pharm., (1977), 13, pp. 362-367.

117. Symes, A., Sourkes, T.L., Biochemical Pharmacology, (1974), 23, pp. 2045-2056.

118. Tipton, K.F., Biochem. J., (1972), 128, pp. 913-919.

- 256 -

119. McEwen, C.M., et. al., Biochemistry, (1969), 8, pp. 3963-3972.

120. Baldessarini, R.J., Greiner, E., Biochemical Pharmacology, (1973), 22, pp. 249-256.

121. Guldberg, H.C., Marsden, C.A., Pharmacological Reviews, (1975), 27, pp. 135-206.

122. Olsen, R.W., et. al., Mol. Pharm., (1975), 11, pp. 558-565.

123. Johnson, G.A., et. al., Journal of Neurochemistry, (1976), 26, pp. 1029-1032.

124. Johnson, G.A., Iversen, L.L., Journal of Neurochemistry, (1971), 18, pp. 1939-1950.

125. Simon, J.R., Martin, D.L., Archives of Biochemistry and Biophysics, (1973), 157, pp. 348-355.

126. Springer, R.H., et. al., Journal of Med. Chem., (1967), 19, pp. 291-296.

127. Baker, B.R., Kozma, J., Journal of Med. Chemistry, (1967), 10, pp. 682-685.

128. Baker, B.R., Wood, W.F., Journal of Med. Chemistry, (1967), 10, pp. 1101-1105.

129. Spector, T., Johns, D.G., Journal of Biol. Chemistry, (1970), 245, pp. 5079-5085.

130. Baldwin, J.J., et. al., Journal of Med. Chemistry, (1975), 18, pp. 895-900.

131. Duggan, D.E., et. al., Journal of Med. Chemistry, (1975), 18, pp. 900-905.

132. Ferraccioli, G., et. al., J. Rheumatol, (1984), 11, pp. 330-332.

133. Iwata, H., et. al., Biochemical Pharm., (1969), 18, pp. 955-957.

134. Iwata, H., et. al., Biochemical Pharm., (1973), 22, pp. 1845-1854.

135. Huszti, Z., Sourkes, T.L., Journal of Pharm. Exp. Therp., (1975), 192, pp. 432-440.

136. Leinweber, F.J., Braun, G.A., Mol. Pharm., (1970), 6, pp. 146-155.

137. Lorenz, W., Werle, E., Bioch. Pharm., (1969), 17, pp. 539-549.

138. Ellenborgen, L., et. al., Biochem. Pharm., (1973), 22, pp. 939-947.

139. Ellenborgen, L., et. al., Biochem. Pharm., (1969), 18, pp. 683-685.

140. Alston, T.A., Abeles, R.H., Biochemistry, (1987), 26, pp. 4082-4085.

- 258 -

141. Ellenbogen, L., et. al., Biochem. Pharm., (1969), 18, pp. 683-685.

142. Lukes, J.J., Neiforth, K.A., Journal of Med. Chemistry, (1975), 18, pp. 351-354.

143. Collins, D., Journal of Biol, Chemistry, (1974), 249, pp. 136-142.

144. Kandutsch, A.A., Chen, H.W., Journal of Biol. Chemistry, (1974), 249, pp. 6057-6061.

145. Kandutsch, A.A., Chen, H.W., Journal of Biol. Chemistry, (1973), 248, pp. 8408-8417.

146. Kupiecki, F.P., Marshall, N.B., Journal of Pharm. Exp.. Therp., (1968), 160, pp. 166-170.

147. Kypson, J., Hait, G., Journal of Pharm. Exp. Therp., (1976), 199, pp. 565-574.

148. Pereira, J.N., Holland, G.F., Journal. Pharm. Exp. Therp., (1967), 157, pp. 381-387.

149. Dulin, W.E., et. al., Proceedings of the Society for Experimental Biology and Medicine, (1965), 118, pp. 499-501.

150. Dulin, W.E., Gerritsen, G.C., Proceedings of the Society for Experimental Biology and Medicine, (1966), 121, pp. 777-779.

151. Waldvogel, E.R.F., et. al., Mol. Pharm., (1967), 3, pp. 429-441.

- 259 -

152. Lowenstein, J.M., Journal of Biol. Chemistry, (1971), 246, pp. 629-632.

153. Maragoudakis, M.E., Journal of Biol. Chemistry, (1971), 246, pp. 4046-4052.

154. Maragoudakis, M.E., Hankin, H., Journal of Biol. Chemistry, (1971), 246, pp. 348-358.

155. Hashimoto, T., et. al., Eur, J., Biochem., (1971), 24, pp. 128-139.

156. Maragoudakis, M.E., Biochemistry, (1970), 9, pp. 413-417.

157. Brady, R.O., Biochem. Biophys. Acta, (1963), 70, pp. 467-468.

158. Rokujo, T., et. al., Life Sciences, (1970), 9, pp. 379-385.

159. Dalton, C., et. al., Prostaglandins, (1974), 7, pp. 319-327.

160. Windmueller, H.G., Levy, R.I., Journal of Biol. Chemistry, (1967), 9, pp. 2246-2254.

161. Roheim, P.S., et. al., Biochem. Biophys. Research. Comm., (1965), 20, pp. 416-421.

162. Smith, D.A., et. al., Geriatics, (1987), 42, pp. 55-62.

- 260 -

163. Falcon, M.G., Jones, B.R., Journal of Gen. Virol., (1977), 36, pp. 199-202.

164. Meek, E.S., Takahashi, M., Nature, (1968), 220, p. 882.

165. De Clercq, E., Luczak, M., Life Sciences, (1975), 17, pp. 187-194.

166. Becker, Y., Pharmac. Ther., (1980), 10, pp. 119-159.

167. Asano, T., Ochiai, Y., Mol. Pharm., (1977), 13, pp. 400-406.

168. Iwai, H., Journal of Biochem., (1974), 76, pp. 419-429.

169. Lippmann, W., Experientia, (1974), 30, pp. 237-239.

170. Nikaido, T., et. al., Planta Medica, (1981), 43, pp. 18-23.

171. Vigdahl, R.L., et. al., Biochem. Biophys. Research Comm., (1971), 42, pp. 1088-1094.

172. Tateson, J.E., Trist, D.G., Life Sciences, (1976), 18, pp. 153-162.

173. Evans, D.P., Thomson, D.S., Br. J. Pharmac., (1975), 53, pp. 409-418.

174. Simmonds, H.A., et. al., Lancet, (1978), Jan. 14, pp. 60-63.

- 261 -

175. Trotta, P.P., et. al., Mol. Pharm., (1978), 14, pp. 199-209.

176. Deibel, M.R., et. al., Biochemical Medicine, (1981), 25, pp. 288-297.

177. Humphrey, S.M., et. al., Journal of Surgical Research, (1987), 43, pp. 187-195.

178. Beard, N.A., et. al., Br. J. Pharmac., (1975), 54, pp. 65-74.

179. Chignard, M., Vargafting, B.B., Prostaglandins, (1977), 14, pp. 222-240.

180. Panganamala, R.V., et. al., Prostaglandins, (1977), 14, pp. 261-271.

181. Kulkarni, P.S., Eakins, K.E., Prostaglandins, (1976), 12, pp. 465-469.

182. Downing, D.T., et. al., Biochem., Biophys. Research Comm., (1970), 40, pp. 218-223.

183. Gorman, R.R., et. al., Biochem. Biophys. Research Comm., (1977), 79, pp. 305-313.

184. Cushman, D.W., Cheung, H.S., Biochem. Biophys. Acta, (1976), 424, pp. 449-459.

185. Taylor, R.J., Salata, J.J., Biochemical Pharmacology, (1976), 25, pp. 2479-2484.

- 262 -

186. Ku, E.C., et. al., Biochemical Pharmacology, (1975), 24, pp. 641-643.

187. Burghuber, O.C., et. al., Am. Rev. Respir. Dis., (1985), 131, pp. 778-785.

188. Michelot, R.J., et. al., Mol. Pharm., (1977), 13, pp. 368-373.

189. Kessel, D., McElhinney, R.S., Biochemical Pharmacology, (1975), 24, pp. 133-137.

190. Gale, G.R., et. al., J. Med. Chem., (1970), 13, pp. 571-574.

191. The Molecular Basis of Antibiotic Action, ed. by E.F. Gale, (1981), pp. 258-401.

192. Hillcoat, B.L., et. al., J. Biol. Chem., (1967), 242, pp. 4777-4781.

193. Carlin, S., et. al., Mol. Pharm., (1974), 10, pp. 194-203.

194. Johns, D.G., et. al., Biochemical Pharmacology, (1970), 19, pp. 1528-1533.

195. Baker, B.R., et. al., J. Med. Chem., (1967), 10, pp. 1134-1138.

196. Baker, B.R., Lourens, G.J., J. Med. Chem., (1968), 11, pp. 666-672.

- 263 -

197. Nair, M.G., et. al., J. Med. Chem., (1974), 17, pp. 1268-1272.

198. Ferone, R., J. Biol. Chem., (1970), 245, pp. 850-854.

199. LaFon, S.W., et. al., J. Biol. Chem., (1985), 260, pp. 9660-9665.

200. Spector, T., Miller, R.L., Biochemica et. Biophysica Acta, (1976), 445, pp. 509-517.

201. Advances in Enzymology, ed. by Alton Meister, (1987) pp. 59-101.

202. Umezawa, H., Ann. Rev. Microbiol., (1982), 36, pp. 75-99.

203. Walsh, C.T., Ann. Rev. Biochem., (1984), 53, pp. 493-535.

204. Demain, A., Biochem. Soc. Symp., (1983), 48, pp. 117-132.

205. Suhadolnik, R.J., Progress in Nucleic Acid Research and Moleulor Biology, (1979), 22, pp. 193-291.

206. Free, C.A., et. al., Biochem. Pharm., (1971), 20, pp. 1421-1428.

207. Enzymes, Dixon, M. and Webb., E.C., Academic Press Inc., N.Y., N.Y., (1964), p. 407.

- 264 -

208. Kondo, T., et. al., Diabetes Care, (1982), vol. 5, Number 3, pp. 218-221.

209. Higgins, I.J., Hill, H.A.O., Plotkin, E.V., Eur. Pat. Appl. EP78,636.

210. Miller, L.L., J. Electroanal. Chem., (1981), 117, pp. 267-281.

211. Mills, R.L., U.S. Patent Appl. 784,243.

212. Gros, P., et. al., Cell, (1986), 47, pp. 371-380.

213. Sanchez-Pescador, R., et. al., Science, (1985), 277, pp. 484-492.

214. The Enzymes, ed. by Paul D. Boyer, (1975), 3rd edition, Vol. XII, Part B, Academic Press, N.Y., N.Y.

215. De Clercq, E., and Balzarini, J., Antiviral Research, Suppl. I, (1985), pp. 89-94.

- 265 -

C L A I M S

What is claimed is:

1.   A chemical compound having the formula A-B-C,
where

A is an energy donor functionality activatable
by an intracellular compartment environment and
capable of transferring energy from its own excited
state to the B functionality;

B is an energy acceptor functionality which
receives energy from A to achieve an excited state;
and

C is a drug moiety covalently bonded to B,
wherein the relaxation of the excited state of B
causes heterolytic cleavage to the covalent bond of
C, releasing C to the intracellular compartment.

2.   The chemical compound of claim 1, further
including D, an energy transfer functionality
covalently bonded to A, having a compound
formula D-A-B-C.

3.   The chemical compound of claim 1, further
including D, an energy transfer functionality,
covalently bonded to A and B, having a compound
formula A-D-B-C.

4.   The chemical compound of claim 1, further
including, D, an energy transfer functionality,
covalently bonded to B, having a compound
formula A-B-C.
           |
           D

5. The chemical compound of claim 1, wherein A comprises a molecule selected from the group comprising thermal, nuclear, chemical vibrational, and chemical electronic energy donor functionalities.

6. The chemical compound of claim 5, wherein A comprises a chemiluminescent molecule.

7. The chemical compound of claim 6, wherein said chemiluminescent compound comprises a compound selected from table 1.

8. The chemical compound of claim 1, wherein B comprises a chromophore.

9. The chemical compound of claim 8, wherein said chromophore comprises a molecule selected from table 2.

10. The compound of claim 1, wherein C effects a therapeutic functional change and comprises a molecule which bonds to a receptor including functional macromolecular components including enzymes, proteins, nucleic acids and ions or which is incorporated into cellular components.

11. The chemical compound of claim 10, wherein C comprises drugs selected from table 3 and the exemplary luminide pharmaceuticals section.

12. The chemical compound of claim 2, wherein D is a molecule comprising a member of a redox pair.

13. The chemical compound of claim 12, wherein D is a molecule selected from table 4.

14. The chemical compound of claim 1, wherein the excited state of the high energy functionality includes electrons derived from the electron carriers of the organism to which the compound was administered.

15. The chemical compound of claim 2, wherein the drug is delivered to the desired site according to one of the permeability of said hybrid molecule to the desired cellular, the biological compartment and the resistance of said hybrid molecule to degradation or elimination.

16. A pharmacentical composition comprising an effective dosage of the compound of claim 1, in combination with an acceptable form of pharmacentical carrier for the therapatic treatment at least one of infectious disease, autoimmune disease, cancer, hyperlipidemia, elevated cholesterol levels, epilepsy, transplant rejection, throboembolic disease, asthma, allergies, hypersensitivity reactions, disorders of nucleotide metabolism, anemia, heart failure, hypertension, depression, ulcer disease, edema, ischemic heart disease, opiate withdrawal, muscular dystrophy, pregnancy prevention, hypercoagulability, arrhythmia, arthritis, therapeutic abortion, gout, and hyperuricemia.

17. The pharmaceutical composition of claim 16, comprising an effective amount of the compound of claim 1 selected to effect a therapeutic functional change.

- 268 -

18. The pharmaceutical composition of claim 16, wherein said pharmaceutical carrier comprises at least one of tragacanth, talc, agar-agar, lactose, polyglycols, ethanol and water.

19. The pharmaceutical composition of claim 16, having the form of a tablet liquid, gel, cream, ointment or lotion.

20. A method of treatment, comprising the step:

Administering an effective amount of the compound of claim 11.

21. The method of treatment of claim 20, wherein the step of administering comprises one of topical application, injection and oral administration.

22. The method of treatment of claim 20, further comprising the step of repeated application of an effective amount of the compound of claim 11.

23. A method for releasing in active form and for transporting an effector of a therapeutic functional change into at least one of an intracellular and a biological compartment to the vicinity of its site of action comprising the steps of:

selecting A as an energy donor functionality;

selecting B as an energy acceptor functionality;

selecting C as the functional modifier;

preparing a pharmaceutical chemical having the general structure A-B-C;

administering the pharmaceutical chemical to the organism having said response to said modifier when delivered in active form within said intracellular or biological compartment;

- 269 -

activating A from the metabolic process wherein an energy transfer from A to B is produced;

releasing C from B in response to the energy transfer from A to B;

effecting a therapeutic functional change by the action of released C.

24. A method of effecting a therapeutic functional change, comprising the steps of:

preparing a metabolically active compound of claim 1;

administering the metabolically activated compound to an environment including said intracellular environment;

activating said metabolically activated compound by the metabolic activity of said cellular target; and

combining a portion of said metabolically activated compound with said modifiable target to effect a therapeutic functional change.

25. A system for effecting a therapeutic functional change comprising:

a hybrid molecule including a drug molecule and a reversible bond to another molecule; and

means for breaking said reversible bond, releasing said drug molecule to effect a therapeutic functional change.

26. The system of claim 25, wherein said reversible bond releases said drug molecule upon an energy transfer; and

said means for reversing said reversible bond is said energy transfer.

- 270 -

27. The system of claim 25, wherein said hybrid molecule includes a photochromic element, and

said means for reversing said reversible bond comprises a chemiluminescent compound.

28. The system of claim 27, wherein said hybrid molecule comprises a luminide, wherein said luminide permeates specific desired biological or cellular compartment and is resistant to inactivation or elimination.

29. A method of effecting a therapeutic functional change of an organism comprising the steps of:

providing a first molecule;

reversibly bonding a second, drug molecule thereto to form a hybrid molecule;

placing the hybrid molecule intracellularly;

breaking said reversible bond causing said drug molecule to be released;

effecting a functional therapeutic change to said organism by action of said released drug molecules.

30. A luminide class chemical compound comprising:

an energy source providing a source of quantum mechanical energy transfer from localized metabolic activity;

an energy acceptor receiving said quantum mechanical energy transfer; and

a drug reversibly bonded to said energy acceptor, wherein,

said energy transfer is activated upon the metabolic production of peroxides and oxygen free radicals by cellular metabolism,

said drug, having been released from said energy acceptor, bonds to a site of action, and

the bonding of said drug to said site effects a therapeutic functional change.

31. The chemical compound of claim 30, further comprising:

receptor mediated mechanisms for providing therapeutic functional change including;

at least one of reversible and irreversible competitive agonism;

antagonism including at least one of a suicide substrate, a transition state analogue mechanism, a noncompetitive or uncompetitive agonism, an antagonism; and

a nonreceptor mediated mechanism including a counterfeit incorporation mechanism.

32. The chemical compound of claim 30, wherein:

said energy acceptor is responsive to a selected molecule in the ambient extracellular environment, and

said drug released in relation to said selected molecule causing a moderation of said selected molecule.

33. The chemical compound of claim 31, wherein:

said selected molecule comprising glucose, and

said drug released comprises insulin.

34. The chemical compound of claim 31, wherein:

said selected molecule comprises degredation products of parines, and

said drug released comprises tissue plasminogen activator (TPA).

35. The chemical compound of claim 1, further comprising:

     a polymer; and immobilized enzyme molecules.

36. The chemical compound of claim 35, wherein:
     said polymer of claim 32 is conducting.

37. The chemical compound of claim 35, wherein:
     said polymer is biocompatible.

38. The chemical compound of claim 35, wherein:
     enzyme of claim 32 comprises at least one of glucose oxidase xanthine oxidase.

39. The chemical compound of claims 32 which further including a monoclonal antibody molecule.

40. The chemical compound of claim 1, further comprising an electrocalalytic polymer.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US89/013 6.1

II FIELDS SEARCHED

Minimum Documentation Searched 7

Classification System	Classification Symbols
U.S.Cl.:	435/5,6; 534/573; 514/150,151; 935/78

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched 8

III DOCUMENTS CONSIDERED TO BE RELEVANT 9

Category *	Citation of Document, 11 with indication, where appropriate, of the relevant passages 12	Relevant to Claim No 13
X	US, A, 3,798,131 (ROUNDS) published 19 March 1974, see entire document.	1-40
X	US, A, 4,599,303 (YABUSAKI) published 08 July 1986, see entire document.	1-40
X	US, A, 4,626,501 (LANDES) published 02 December 1986, see entire document.	1-40
X	US, A, 4,656,127 (MUNDY) published 07 April 1987, see entire document.	1-40
X	US, A, 4,683,194 (SAIKI) published 28 July 1987, see entire document.	1-40
X	US, A, 4,716,106 (CHISWELL) published 29 December 1987, see entire document.	1-40

* Special categories of cited documents: 10

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report
23 JUNE 1989	**06 SEP 1989**

International Searching Authority	Signature of Authorized Officer
ISA/US	FLOYD D. HIGEL